Pfizer (PFE) 10-Q 7 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 29, 2019	Nov. 04, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 29, 2019
Document Transition Report	false
Entity File Number	1-3619
Entity Registrant Name	PFIZER INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-5315170
Entity Address, Address Line One	235 East 42nd Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	733-2323
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,534,122,364
Entity Central Index Key	0000078003
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock, $.05 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $.05 par value
Trading Symbol	PFE
Security Exchange Name	NYSE
0.000% Notes due 2020 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.000% Notes due 2020
Trading Symbol	PFE20A
Security Exchange Name	NYSE
0.250% Notes due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes due 2022
Trading Symbol	PFE22
Security Exchange Name	NYSE
1.000% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2027
Trading Symbol	PFE27
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Costs and expenses:
Cost of sales	[1],[2]	2,602	2,694	7,611	8,173
Selling, informational and administrative expenses	[1],[2]	3,260	3,494	10,110	10,448
Research and development expenses	[1],[2]	2,283	2,008	5,827	5,549
Amortization of intangible assets	[1]	1,212	1,253	3,578	3,640
Restructuring charges and certain acquisition-related costs	[1]	365	85	295	172
(Gain) on completion of Consumer Healthcare JV transaction	[1]	(8,087)	0	(8,087)	0
Other (income)/deductions––net	[1]	319	(414)	537	(1,143)
Income from continuing operations before provision for taxes on income	[1],[3]	10,727	4,177	19,190	12,831
Provision for taxes on income	[1]	3,047	66	2,566	1,270
Income from continuing operations	[1]	7,680	4,111	16,625	11,562
Discontinued operations––net of tax	[1]	4	11	4	10
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	7,684	4,122	16,628	11,571
Less: Net income attributable to noncontrolling interests	[1]	4	8	19	25
Net income attributable to Pfizer Inc.	[1]	$ 7,680	$ 4,114	$ 16,609	$ 11,546
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.38	$ 0.70	$ 2.98	$ 1.96
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.38	0.70	2.98	1.96
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.36	0.69	2.92	1.92
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.36	$ 0.69	$ 2.92	$ 1.92
Weighted-average shares––basic	[1]	5,545	5,875	5,581	5,899
Weighted-average shares––diluted	[1]	5,649	5,986	5,690	5,998
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018 , and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 7,684	$ 4,122	$ 16,628	$ 11,571
Foreign currency translation adjustments, net	[4]	(468)	(567)	(628)	(507)
Reclassification adjustments	[4],[5]	268	(2)	270	(22)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[4]	(200)	(569)	(358)	(530)
Unrealized holding gains on derivative financial instruments, net	[4]	150	222	241	236
Reclassification adjustments for (gains)/losses included in net income	[4],[6]	(29)	(235)	(372)	119
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[4]	122	(13)	(131)	355
Unrealized holding gains/(losses) on available-for-sale securities, net	[4]	15	149	48	(65)
Reclassification adjustments for (gains)/losses included in net income	[4],[6]	(7)	(36)	30	(67)
Reclassification adjustments for unrealized gains included in Retained earnings	[4],[7]	0	0	0	(462)
Other comprehensive income (loss), available-for-sale securities, before tax, total	[4]	8	112	77	(595)
Benefit plans: actuarial gains/(losses), net	[4]	(171)	8	(175)	114
Reclassification adjustments related to amortization	[4]	60	60	180	183
Reclassification adjustments related to settlements, net	[4]	38	42	40	108
Other	[4]	42	49	60	69
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[4]	(31)	158	105	474
Benefit plans: prior service costs and other, net	[4]	0	0	(1)	0
Reclassification adjustments related to amortization of prior service costs and other, net	[4]	(44)	(46)	(137)	(137)
Reclassification adjustments related to curtailments of prior service costs and other, net	[4]	(46)	(4)	(46)	(18)
Other	[4]	3	0	4	1
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[4]	(88)	(50)	(180)	(154)
Other comprehensive loss, before tax	[4]	(190)	(361)	(486)	(449)
Tax provision on other comprehensive loss	[4]	84	62	50	667
Other comprehensive loss before allocation to noncontrolling interests	[2],[4]	(275)	(422)	(536)	(1,116)
Comprehensive income before allocation to noncontrolling interests	[4]	7,409	3,700	16,092	10,455
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[4]	(6)	0	8	5
Comprehensive income attributable to Pfizer Inc.	[4]	$ 7,415	$ 3,700	$ 16,084	$ 10,450
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	For the third quarter and first nine months of 2019, the foreign currency translation adjustments are primarily reclassified into (Gain) on completion of Consumer Healthcare JV transaction in the condensed consolidated statements of income as a result of the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK. See Note 2B. The remaining foreign currency translation adjustments are reclassified into Other (income)/deductions—net in the condensed consolidated statements of income .
[6]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[7]	For additional information, see Notes to Consolidated Financial Statements —Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	[1]	$ 2,785	$ 1,139	[2]
Short-term investments	[1]	6,302	17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019—$541; 2018—$541	[1]	9,439	8,025
Inventories	[1],[3]	8,222	7,508
Current tax assets	[1]	3,730	3,374
Other current assets	[1]	2,954	2,461
Assets held for sale	[1]	29	9,725
Total current assets	[1]	33,459	49,926
Equity-method investments	[1]	15,999	181
Long-term investments	[1]	2,723	2,586
Property, plant and equipment, less accumulated depreciation: 2019—$16,728; 2018—$16,591	[1]	13,701	13,385
Identifiable intangible assets, less accumulated amortization	[1],[4],[5]	38,995	35,211
Goodwill	[1]	58,665	53,411
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,984	1,924
Other noncurrent assets	[1]	4,920	2,799
Total assets	[1]	170,446	159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019—$2,431; 2018—$4,776	[1]	16,617	8,831
Trade accounts payable	[1]	3,942	4,674
Dividends payable	[1]	1,992	2,047
Income taxes payable	[1]	1,892	1,265
Accrued compensation and related items	[1]	2,369	2,397
Other current liabilities	[1]	10,160	10,753
Liabilities held for sale	[1]	0	1,890
Total current liabilities	[1]	36,974	31,858
Long-term debt	[1]	36,044	32,909
Pension benefit obligations, net	[1]	5,103	5,272
Postretirement benefit obligations, net	[1]	1,321	1,338
Noncurrent deferred tax liabilities	[1]	6,724	3,700
Other taxes payable	[1]	12,504	14,737
Other noncurrent liabilities	[1]	6,381	5,850
Total liabilities	[1]	105,051	95,664
Commitments and Contingencies	[1]
Preferred stock	[1]	18	19
Common stock	[1]	468	467
Additional paid-in capital	[1]	87,099	86,253
Treasury stock	[1]	(110,795)	(101,610)
Retained earnings	[1]	100,113	89,554
Accumulated other comprehensive loss	[1]	(11,801)	(11,275)
Total Pfizer Inc. shareholders’ equity	[1]	65,103	63,407
Equity attributable to noncontrolling interests	[1]	293	351
Total equity	[1],[6]	65,396	63,758
Total liabilities and equity	[1]	$ 170,446	$ 159,422
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C ).
[4]	The increase in I dentifiable intangible assets, less accumulated amortization , is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments.
[5]	The increase in the gross carrying amount of I dentifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreement s (see Note 2A ).
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 541	$ 541
Property, plant and equipment, accumulated depreciation	[1]	16,728	16,591
Current portion of long-term debt	[1]	$ 2,431	$ 4,776
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Millions		Total		Preferred Stock [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Shareholders' Equity [Member]	Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2017	[1]			524	9,275,000,000		(3,296,000,000)
Beginning balance at Dec. 31, 2017	[1]	$ 71,656		$ 21	$ 464	$ 84,278	$ (89,425)	$ 85,291	$ (9,321)	$ 71,308	$ 348
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	11,571	[2],[3],[4]					11,546		11,546	25
Other comprehensive income/(loss), net of tax	[1]	(1,116)	[4]						(1,096)	(1,096)	(20)
Cash dividends declared:
Common stock	[1]	(6,012)						(6,012)		(6,012)
Preferred stock	[1]	(1)						(1)		(1)
Noncontrolling interests	[1]	(7)									(7)
Share-based payment transactions (in shares)	[1]				51,000,000		3,000,000
Share-based payment transactions	[1]	1,573			$ 3	1,551	$ 19			1,573
Purchases of common stock (in shares)	[1]						(192,000,000)
Purchases of common stock	[1]	(7,168)					$ (7,168)			(7,168)
Preferred stock conversions and redemptions (in shares)	[1]			(36)
Preferred stock conversions and redemptions	[1]	(3)		$ (1)		(2)				(3)
Other	[1],[5]	1,171						1,171		1,171
Ending balance (in shares) at Sep. 30, 2018	[1]			488	9,326,000,000		(3,484,000,000)
Ending balance at Sep. 30, 2018	[1]	71,664		$ 20	$ 466	85,828	$ (96,574)	91,995	(10,417)	71,319	346
Beginning balance (in shares) at Jul. 01, 2018	[1]			502	9,303,000,000		(3,438,000,000)
Beginning balance at Jul. 01, 2018	[1]	70,124		$ 20	$ 465	84,898	$ (95,463)	89,860	(10,003)	69,778	346
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	4,122	[2],[3],[4]					4,114		4,114	8
Other comprehensive income/(loss), net of tax	[1]	(422)	[4]						(414)	(414)	(9)
Cash dividends declared:
Common stock	[1]	(1,977)						(1,977)		(1,977)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	0									0
Share-based payment transactions (in shares)	[1]				23,000,000
Share-based payment transactions	[1]	926			$ 1	930	$ (6)			926
Purchases of common stock (in shares)	[1]						(47,000,000)
Purchases of common stock	[1]	(1,105)					$ (1,105)			(1,105)
Preferred stock conversions and redemptions (in shares)	[1]			(14)
Preferred stock conversions and redemptions	[1]	(1)		$ (1)		(1)				(1)
Other	[1]	(2)						(2)		(2)
Ending balance (in shares) at Sep. 30, 2018	[1]			488	9,326,000,000		(3,484,000,000)
Ending balance at Sep. 30, 2018	[1]	71,664		$ 20	$ 466	85,828	$ (96,574)	91,995	(10,417)	71,319	346
Beginning balance (in shares) at Dec. 31, 2018	[1]			478	9,332,000,000		(3,615,000,000)
Beginning balance at Dec. 31, 2018	[1]	63,758	[6]	$ 19	$ 467	86,253	$ (101,610)	89,554	(11,275)	63,407	351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	16,628	[2],[3],[4]					16,609		16,609	19
Other comprehensive income/(loss), net of tax	[1]	(536)	[4]						(525)	(525)	(11)
Cash dividends declared:
Common stock	[1]	(6,068)						(6,068)		(6,068)
Preferred stock	[1]	(1)						(1)		(1)
Noncontrolling interests	[1]	(5)									(5)
Share-based payment transactions (in shares)	[1]				34,000,000		(7,000,000)
Share-based payment transactions	[1]	530			$ 2	848	$ (320)			530
Purchases of common stock (in shares)	[1]						(213,000,000)
Purchases of common stock	[1]	(8,865)					$ (8,865)
Preferred stock conversions and redemptions (in shares)	[1]			(28)
Preferred stock conversions and redemptions	[1]	(3)		$ (1)		(2)				(3)
Other	[1],[7]	(42)						19		19	(61)
Ending balance (in shares) at Sep. 29, 2019	[1]			449	9,366,000,000		(3,835,000,000)
Ending balance at Sep. 29, 2019	[1]	65,396	[6]	$ 18	$ 468	87,099	$ (110,795)	100,113	(11,801)	65,103	293
Beginning balance (in shares) at Jun. 30, 2019	[1]			458	9,363,000,000		(3,801,000,000)
Beginning balance at Jun. 30, 2019	[1]	59,924		$ 18	$ 468	86,963	$ (110,786)	94,440	(11,535)	59,568	357
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	7,684	[2],[3],[4]					7,680		7,680	4
Other comprehensive income/(loss), net of tax	[1]	(275)	[4]						(265)	(265)	(9)
Cash dividends declared:
Common stock	[1]	(2,006)						(2,006)		(2,006)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	2									2
Share-based payment transactions (in shares)	[1]				3,000,000		0
Share-based payment transactions	[1]	128			$ 0	136	$ (8)			128
Purchases of common stock (in shares)	[1]						(34,000,000)
Purchases of common stock	[1]	0					$ 0			0
Preferred stock conversions and redemptions (in shares)	[1]			(8)
Preferred stock conversions and redemptions	[1]	(1)		$ 0		0				(1)
Other	[1],[7]	(61)						0	0	0	(61)
Ending balance (in shares) at Sep. 29, 2019	[1]			449	9,366,000,000		(3,835,000,000)
Ending balance at Sep. 29, 2019	[1]	$ 65,396	[6]	$ 18	$ 468	$ 87,099	$ (110,795)	$ 100,113	$ (11,801)	$ 65,103	$ 293
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from Accumulated other comprehensive income . For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
[6]	Amounts may not add due to rounding.
[7]	The increase to Retained earnings in the first nine months of 2019 includes the cumulative effect of the adoption of a new accounting standard for leases in the first quarter of 2019. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards . The decrease in Equity attributable to n oncontrolling interests resulted from the deconsolidation of our Consumer Healthcare business in connection with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement : Equity-Method Investment and Assets and Liabilities Held for Sale .

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 16,628	$ 11,571
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[3]	4,626	4,743
Asset write-offs and impairments	[3]	224	88
TCJA impact	[3],[5]	(319)	(410)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[3],[6]	(8,233)	0
Deferred taxes from continuing operations(c)	[3],[7]	2,067	(974)
Share-based compensation expense	[3]	448	682
Benefit plan contributions in excess of income	[3]	(429)	(1,000)
Other adjustments, net	[3]	(622)	(1,170)
Other changes in assets and liabilities, net of acquisitions and divestitures	[3]	(5,571)	(2,441)
Net cash provided by operating activities	[3]	8,819	11,089
Investing Activities
Purchases of property, plant and equipment	[3]	(1,504)	(1,357)
Purchases of short-term investments	[3]	(4,583)	(7,364)
Proceeds from redemptions/sales of short-term investments	[3]	7,766	12,752
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[3]	8,307	385
Purchases of long-term investments	[3]	(134)	(1,503)
Proceeds from redemptions/sales of long-term investments	[3]	116	2,174
Acquisition of business, net of cash acquired	[3]	(10,861)	0
Acquisitions of intangible assets	[3]	(364)	(47)
Other investing activities, net	[3],[6]	145	248
Net cash provided by/(used in) investing activities	[3]	(1,112)	5,289
Financing Activities
Proceeds from short-term borrowings	[3]	11,582	1,945
Principal payments on short-term borrowings	[3]	(4,088)	(4,239)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[3]	2,604	(973)
Proceeds from issuance of long-term debt	[3]	4,942	4,974
Principal payments on long-term debt	[3]	(5,806)	(3,104)
Purchases of common stock	[3]	(8,865)	(7,168)
Cash dividends paid	[3]	(6,051)	(6,015)
Proceeds from exercise of stock options	[3]	303	1,099
Other financing activities, net	[3]	(667)	(553)
Net cash used in financing activities	[3]	(6,045)	(14,034)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[3]	(41)	(116)
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[3]	1,620	2,227
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[3]	1,225	1,431
Cash and cash equivalents and restricted cash and cash equivalents, end	[3]	2,846	3,658
Cash paid (received) during the period for:
Income taxes	[3]	2,636	1,666
Interest paid	[3]	1,246	968
Interest rate hedges	[3]	(78)	(104)
GSK Consumer Healthcare [Member]
Non-cash transactions:
Equity investment in exchange for assets	[3],[6]	15,711	0
Cerevel Therapeutics, Inc. [Member]
Non-cash transactions:
Equity investment in exchange for assets	[3],[8]	0	343
Allogene [Member]
Non-cash transactions:
Equity investment in exchange for assets	[3],[8]	$ 0	$ 92
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for (i) the nine months ended September 29, 2019 was favorably impacted by approximately $319 million , primarily as a result of additional guidance issued by the U.S. Department of Treasury and (ii) the nine months ended September 30, 2018 was favorably impacted by approximately $410 million , primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.
[6]	The $8.2 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity-method investment in the new company valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net . For additional information, see Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement : Equity-Method Investment and Assets and Liabilities Held for Sale .
[7]	Includes tax expense of $2.7 billion associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK. For additional information, see Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement : Equity-Method Investment and Assets and Liabilities Held for Sale and Note 5A. Tax Matters: Taxes on Income from Continuing Operations.
[8]	For additional information, see Notes to Consolidated Financial Statements–– Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Divestitures: Divestitures in our 2018 Financial Report.

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) $ in Millions	Jul. 31, 2019USD ($)
GSK Consumer Healthcare [Member]
Equity method investment, ownership percentage	32.00%
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	$ 8,200
Fair value of equity method investment	15,700
Net assets contributed	7,600
Cash conveyed	$ 146

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 25, 2019 and August 26, 2018 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended September 29, 2019 and September 30, 2018 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2018 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . In addition, certain amounts within Long-term investments in the December 31, 2018 condensed consolidated balance sheet have been reclassified to Equity-method investments to conform to the current presentation. For additional information, see Note 2B. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. In the first quarter of 2019 , as of January 1, 2019 , we adopted four new accounting standards. See Note 1B for further information. Our recent significant business development activities include: • Formation of a New Consumer Healthcare Joint Venture ––On July 31, 2019 , we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In accordance with our domestic and international reporting periods, our financial results, and our Consumer Healthcare segment’s operating results, for the third quarter of 2019 reflect only one month of Consumer Healthcare segment domestic operations and two months of Consumer Healthcare segment international operations. Likewise, our financial results, and our Consumer Healthcare segment’s operating results, for the first nine months of 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. • Acquisition of Array BioPharma Inc. ––On July 30, 2019 , we acquired Array for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ( $10.9 billion , net of cash acquired). Our financial statements for the third quarter and first nine months of 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date. • Agreement to Combine Upjohn with Mylan N.V. ––On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun-off or split-off to Pfizer’s shareholders and, immediately thereafter, combined with Mylan. Pfizer shareholders would own 57% of the combined new company, and former Mylan shareholders would own 43% . The transaction is expected to be tax free to Pfizer and Pfizer shareholders. The transaction is anticipated to close in mid-2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals. • Acquisition of Therachon Holding AG –– On July 1, 2019, we acquired all the remaining shares of Therachon for $340 million upfront, plus potential milestone payments of up to $470 million , contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately $322 million . Our financial statements for the third quarter and first nine months of 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect two months of Therachon operations and cash flows. For additional information, see Note 2 below and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment in Pfizer’s 2018 Financial Report. B. Adoption of New Accounting Standards On January 1, 2019, we adopted four new accounting standards. Leases ––On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of $1.4 billion and current and noncurrent operating lease liabilities of $1.4 billion as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $30 million on a pre-tax basis ( $20 million after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules. Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574 Adoption of the standard related to leases did not have a material impact on our condensed consolidated statements of income or condensed consolidated statements of cash flows for the nine months ended September 29, 2019 . For additional information, see Note 1D . Amortization Period for Certain Callable Debt Securities Held at a Premium ––We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features ––We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Share-Based Payments to Nonemployees ––We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2018, we adopted eleven new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 included in our 2018 Financial Report. C. Revenues and Trade Accounts Receivable Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.6 billion as of September 29, 2019 and $5.4 billion as of December 31, 2018 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) September 29, December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,203 $ 1,288 Other current liabilities : Accrued rebates 3,275 3,208 Other accruals 617 531 Other noncurrent liabilities 463 399 Total accrued rebates and other accruals $ 5,557 $ 5,426 D. Leases On January 1, 2019, we adopted a new accounting standard for leases. For further information, see Note 1B . We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $74 million for the three months ended September 29, 2019 and $192 million for the nine months ended September 29, 2019 . We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes. We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: Balance at (MILLIONS OF DOLLARS) Balance Sheet Classification September 29, ROU assets Other noncurrent assets $ 1,306 Lease liabilities (short-term) Other current liabilities 281 Lease liabilities (long-term) Other noncurrent liabilities 1,037 Our total lease costs are as follows: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, 2019 September 29, 2019 Operating lease cost $ 111 $ 310 Variable lease cost 74 192 Sublease income (10 ) (31 ) Total lease cost $ 174 $ 471 Other supplemental information includes the following: Weighted-Average Remaining Contractual Lease Term (Years) as of Weighted-Average Discount Rate as of (MILLIONS OF DOLLARS) September 29, September 29, Nine Months Ended September 29, 2019 Operating leases 6.8 3.6 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 244 (Gains)/losses on sale and leaseback transactions, net (32 ) ROU assets obtained in exchange for new operating lease liabilities $ 250 The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of September 29, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 322 1-2 years 279 2-3 years 222 3-4 years 176 4-5 years 110 Thereafter 406 Total undiscounted lease payments 1,516 Less: Imputed interest 197 Present Value of Minimum Lease Payments 1,319 Less: Current portion 281 Noncurrent portion $ 1,037 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date. In April 2018, we entered an agreement to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this 20 -year lease is approximately $1.7 billion . Prior to our adoption of the new lease standard, rental expense, net of sublease income, was $301 million in 2018, $314 million in 2017 and $292 million in 2016. As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Acquisitions, Equity-Method Inv

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement	9 Months Ended
	Sep. 29, 2019
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement	Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement A. Acquisitions Array BioPharma Inc. On July 30, 2019 , we acquired Array, a commercial stage biopharmaceutical company focused on targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ( $10.9 billion , net of cash acquired). In addition, approximately $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs in the condensed consolidated statement of income for the three and nine months ended September 29, 2019 (see Note 3 ). We financed the majority of the transaction with debt and the balance with existing cash. Array’s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAF V600E - or BRAF V600K -mutant unresectable or metastatic melanoma. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including the Phase 3 BEACON trial in BRAF-mutant mCRC, through collaborations with third parties. Pfizer has exclusive rights to commercialize the combination therapy in the U.S. and Canada. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in different stages of research and development, as well as a portfolio of out-licensed medicines, which are expected to generate material milestones and royalties over time. In connection with this acquisition, we provisionally recorded: (i) $7.2 billion in Identifiable intangible assets , consisting of $1.8 billion of Developed technology rights with a useful life of 16 years , $4.0 billion of IPR&D and $1.4 billion for Licensing agreements ( $1.1 billion for technology in development –– indefinite-lived licensing agreements and $340 million for developed technology –– finite-lived licensing agreements with a useful life of 10 years ), (ii) $5.4 billion of Goodwill , (iii) $1.3 billion of net deferred tax liabilities and (iv) $451 million of assumed long-term debt, which was paid in full as of September 29, 2019 . The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Therachon Holding AG On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset. In 2018, we acquired approximately 3% of Therachon’s outstanding shares for $5 million . We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was approximately $322 million , which consisted of $317 million of cash and our previous $5 million investment in Therachon. Therachon is a wholly-owned subsidiary of Pfizer. In connection with this asset acquisition, we recorded a charge of $337 million in Research and development expenses. B. Equity-Method Investment and Assets and Liabilities Held for Sale On July 31, 2019 , we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a 32% equity stake in the new company and GSK owns the remaining 68% . Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ( $5.4 billion , net of tax) in our fiscal third quarter of 2019 in (Gain) on completion of Consumer Healthcare JV transaction for the difference in the fair value of our 32% equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. In valuing our investment in GSK Consumer Healthcare, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. As part of the joint venture transaction, we agreed to indemnify GSK with respect to certain tax matters related to periods prior to closing of the transaction as well as certain potential environmental or other legal liabilities associated with the previous operation of our Consumer Healthcare business. We recognized a liability of $45 million with respect to the tax matters indemnification. The value of the environmental and legal indemnifications was not considered to be material. We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. Our investment in GSK Consumer Healthcare is reported as a private equity investment in the Equity-method investments line in our condensed consolidated balance sheet as of September 29, 2019. Our consolidated statements of income for the third quarter and first nine months of 2019 include revenues and expenses associated with Pfizer’s Consumer Healthcare business through July 31, 2019. We will record our share of earnings from the Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in Other (income)/deductions––net commencing from August 1, 2019. Therefore, we will record our share of two months of the joint venture’s earnings generated in the third quarter of 2019 in our operating results in the fourth quarter of 2019. As of the July 31, 2019 closing date, the fair value of our investment in GSK Consumer Healthcare was approximately $15.7 billion . The excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare has not yet been allocated within the investment account. We expect to complete the allocation in our fourth quarter of 2019, and we will record the amortization of identified basis differences, as applicable, on a one-quarter lag in Other (income)/deductions––net commencing August 1, 2019. Therefore, we will record the amortization of identified basis differences for two months of the third quarter of 2019 in our operating results in the fourth quarter of 2019. While we have received our full 32% interest in GSK Consumer Healthcare as of the July 31, 2019 closing and transferred control of our Consumer Healthcare business to GSK Consumer Healthcare, the contribution of the business was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, we have continued to operate the business for the net economic benefit of GSK Consumer Healthcare, and we are indemnified by GSK Consumer Healthcare against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. We expect the contribution of our Consumer Healthcare business in these jurisdictions to be fully completed by the first half of 2021. As such, and as we and GSK Consumer Healthcare are contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes. In connection with the contribution of our Consumer Healthcare business, we entered into certain transitional agreements designed to facilitate the orderly transition of the business to GSK Consumer Healthcare. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain consumer products for GSK Consumer Healthcare and GSK Consumer Healthcare will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of up to six years . These agreements are not material to Pfizer. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheets as of December 31, 2018. The Consumer Healthcare business assets held for sale are reported in Assets held for sale and Consumer Healthcare business liabilities held for sale are reported in Liabilities held for sale in the consolidated balance sheet as of December 31, 2018. This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries. The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following: (MILLIONS OF DOLLARS) December 31, Assets Held for Sale Cash and cash equivalents $ 32 Trade accounts receivable, less allowance for doubtful accounts 532 Inventories 538 Other current assets 56 PP&E 675 Identifiable intangible assets, less accumulated amortization 5,763 Goodwill 1,972 Noncurrent deferred tax assets and other noncurrent tax assets 54 Other noncurrent assets 57 Total Consumer Healthcare assets held for sale 9,678 Other assets held for sale (a) 46 Assets held for sale $ 9,725 Liabilities Held for Sale Trade accounts payable $ 406 Income taxes payable 39 Accrued compensation and related items 93 Other current liabilities 353 Pension benefit obligations, net 39 Postretirement benefit obligations, net 33 Noncurrent deferred tax liabilities 870 Other noncurrent liabilities 56 Total Consumer Healthcare liabilities held for sale $ 1,890 (a) Other assets held for sale consist of PP&E. As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $100 million for the third quarter of 2019 and $654 million for the nine months ended September 29, 2019 , through July 31, 2019, and $211 million for the third quarter of 2018 and $725 million for the nine months ended September 30, 2018 . C. Research and Development Arrangement Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to $200 million in development costs related to certain Phase 3 clinical trials of Pfizer’s rivipansel compound and Pfizer would use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding was expected to cover up to 100% of the development costs and was received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer is responsible for the remaining development costs. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding was recognized by us as an obligation to perform contractual services and therefore a reduction of Research and development expenses as incurred. The funding cap was reached in 2019. Following potential regulatory approval, NovaQuest would be eligible to receive a combination of fixed milestone payments of up to approximately $267 million in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments would be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales would be recorded as Cost of sales when incurred. In August 2019, we announced that the Phase 3 RESET (Rivipansel Evaluating Safety, Efficacy and Time to Discharge) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with IV opioids. As a result, in the third quarter of 2019, we recorded a $127 million charge in Cost of sales related to rivipansel , primarily for inventory manufactured for expected future sale , as well as $15 million of anticipated clinical development program close-out costs, which were recorded in Research and development costs in the condensed consolidated statement of income. Detailed analyses of the RESET study, including additional data on efficacy and safety endpoints, are under review and will be submitted for presentation at a future scientific meeting. Following those detailed analyses, the impact on the NovaQuest agreement will be evaluated.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. 2017-2019 Initiatives and Organizing for Growth During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses –– Biopharma, a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business (see Note 13 ). To operate effectively in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program include activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and optimization of our operating business structure and functions that support them. From 2017 through September 29, 2019 , we incurred approximately $819 million associated with manufacturing optimization, and approximately $945 million associated with other activities. In 2019, we expect restructuring, implementation and additional depreciation charges of about $600 million and, of that amount, we expect approximately 15% of the total charges will be non-cash. Current-Period Key Activities For the first nine months of 2019 , we incurred costs of $452 million composed of $272 million associated with the integration of Array, $300 million associated with the 2017-2019 and Organizing for Growth initiatives and $74 million associated with the integration of Hospira, partially offset by income of $194 million , primarily due to the reversal of certain accruals upon the effective favorable settlement of a U.S. IRS audit for multiple tax years and other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Restructuring charges/(credits): Employee terminations $ 82 $ (24 ) $ (86 ) $ (53 ) Asset impairments 3 12 3 8 Exit costs/(credits) (1 ) 14 33 14 Restructuring charges/(credits) (a) 83 1 (50 ) (32 ) Transaction costs (b) 65 1 65 1 Integration costs and other (c) 217 82 281 202 Restructuring charges and certain acquisition-related costs 365 85 295 172 Net periodic benefit costs recorded in Other (income)/deductions––net 9 41 19 103 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 6 12 21 43 Selling, informational and administrative expenses — — 2 — Research and development expenses — — 6 — Total additional depreciation––asset restructuring 6 12 29 43 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 14 21 45 57 Selling, informational and administrative expenses 23 17 48 51 Research and development expenses 3 9 16 22 Total implementation costs 40 48 109 130 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 420 $ 186 $ 452 $ 447 (a) In the third quarter of 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives as well as our acquisition of Array. In the first nine months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Note 5B ), partially offset by employee termination costs associated with cost-reduction and productivity initiatives, as well as our acquisition of Array. In the third quarter of 2018, restructuring charges were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs. In the first nine months of 2018, restructuring credits were mostly related to the reversal of previously recorded accruals for employee termination costs. The restructuring activities for 2019 are associated with the following: • For the third quarter of 2019 , Biopharma ( $10 million charge ); Upjohn ( $6 million credit ); and Other ( $79 million charge). • For the first nine months of 2019 , Biopharma ( $38 million credit); Upjohn ( $27 million credit ); and Other ( $15 million charge). The restructuring activities for 2018 are associated with the following: • For the third quarter of 2018, total reportable segments ( $6 million credit); and Other ( $7 million charge). • For the first nine months of 2018, total reportable segments ( $30 million credit); and Other ( $2 million credit). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments. (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. In the third quarter and first nine months of 2019, transaction costs relate to our acquisition of Array. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the third quarter and first nine months of 2019, integration costs and other primarily includes $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see Note 2A ). In the third quarter and first nine months of 2018, integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2018 (a) $ 1,203 $ — $ 49 $ 1,252 Provision/(credit) (b) (86 ) 3 33 (50 ) Utilization and other (c) (431 ) (3 ) (33 ) (467 ) Balance, September 29, 2019 (d) $ 686 $ — $ 48 $ 734 (a) Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ). (b) Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Note 5B for additional information. (c) Includes adjustments for foreign currency translation. (d) Included in Other current liabilities ( $535 million ) and Other noncurrent liabilities ( $199 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	9 Months Ended
	Sep. 29, 2019
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Interest income (a) $ (60 ) $ (82 ) (185 ) (240 ) Interest expense (a) 409 310 1,158 946 Net interest expense 348 228 973 706 Royalty-related income (b) (155 ) (143 ) (475 ) (360 ) Net gains on asset disposals (32 ) (4 ) (33 ) (19 ) Net gains recognized during the period on investments in equity securities (c) (6 ) (85 ) (153 ) (460 ) Net realized losses on sales of investments in debt securities — 8 — 19 Income from collaborations, out-licensing arrangements and sales of compound/product rights (d) (20 ) (139 ) (124 ) (455 ) Net periodic benefit credits other than service costs (e) (19 ) (65 ) (110 ) (231 ) Certain legal matters, net (f) 64 37 84 (70 ) Certain asset impairments (g) 28 (1 ) 188 40 Business and legal entity alignment costs (h) 87 1 343 5 Net losses on early retirement of debt (i) — — 138 3 Other, net (j) 24 (252 ) (294 ) (322 ) Other (income)/deductions––net $ 319 $ (414 ) $ 537 $ (1,143 ) (a) Interest income decreased in the third quarter and first nine months of 2019 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2019 , mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year periods. (b) The increase in royalty-related income for the first nine months of 2019 is primarily due to a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million . (c) The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B . (d) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first nine months of 2019 , mainly includes, among other things, $70 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® (fluticasone propionate and salmeterol inhalation powder) and $26 million in milestone income from multiple licensees. In the third quarter of 2018 , primarily included, among other things, (i) $40 million in milestone income from a certain licensee, (ii) a $35 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of Crohn’s disease and (iii) $45 million in gains related to sales of compound/product rights. In the first nine months of 2018 , mainly included, among other things, (i) approximately $128 million in milestone income from multiple licensees, (ii) an upfront payment to us of $75 million for the sale of an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator for cognitive impairment associated with schizophrenia (CIAS) to Biogen Inc., (iii) $110 million in milestone payments received from Shire, of which $75 million was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis and $35 million was received from Shire related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn’s disease, (iv) a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU and (v) $45 million in gains related to sales of compound/product rights. (e) For additional information, see Note 10 . (f) For the first nine months of 2018 , the net credits primarily represented the reversal of a legal accrual where a loss was no longer deemed probable. (g) The first nine months of 2019 include an intangible asset impairment charge of $10 million and the first nine months of 2018 included an intangible asset impairment charge of $31 million recorded in the second quarter of 2018, which are all related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflect , among other things, updated commercial forecasts. The first nine months of 2019 also includes intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first nine months of 2019 , includes other asset impairments of $48 million . (h) In the third quarter and first nine months of 2019, and in the third quarter of 2018, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first nine months of 2018, mainly represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In the first nine months of 2019 , represents net losses due to the early retirement of debt in the first quarter of 2019, inclusive of the related termination of cross-currency swaps. (j) The third quarter of 2019 includes, among other things, dividend income of $43 million from our investment in ViiV and charges of $121 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. The first nine months of 2019 includes, among other things, (i) dividend income of $184 million from our investment in ViiV, (ii) charges of $146 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) $50 million of income from insurance recoveries related to Hurricane Maria. The third quarter and first nine months of 2018 included a non-cash $343 million pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. The third quarter of 2018 also included, among other things, dividend income of $91 million from our investment in ViiV, and charges of $122 million , reflecting the change in the fair value of contingent consideration. The first nine months of 2018 also included, among other things, (i) dividend income of $226 million from our investment in ViiV, (ii) charges of $257 million , reflecting the change in the fair value of contingent consideration, (iii) a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T development program assets obtained from Cellectis S.A. and Les Laboratoires Servier SAS in connection with our contribution agreement entered into with Allogene, and (iv) a non-cash $17 million gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg. The following table provides additional information about the intangible assets that were impaired during 2019 in Other (income)/deductions: Fair Value (a) Nine Months Ended September 29, 2019 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ — $ — $ — $ — $ 90 Intangible assets––Developed technology rights (b) 13 — — 13 50 Total $ 13 $ — $ — $ 13 $ 140 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the first nine months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately $1.4 billion , representing tax and interest. Our effective tax rate for continuing operations was 28.4% for the third quarter of 2019 , compared to 1.6% for the third quarter of 2018 and was 13.4% for the first nine months of 2019 , compared to 9.9% for the first nine months of 2018 . The higher effective tax rate for the third quarter of 2019 in comparison with the same period in 2018 was primarily due to: • the tax expense of $2.7 billion associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; • the non-recurrence of certain tax initiatives and favorable adjustments to the provisional estimate of the legislation commonly referred to as the TCJA; and • a decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations. The higher effective tax rate for the first nine months of 2019 in comparison with the same period in 2018 was primarily due to: • the tax expense of $2.7 billion associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; and • the non-recurrence of certain tax initiatives and favorable adjustments to the provisional estimate of the TCJA, partially offset by: • an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years, primarily resulting from the aforementioned favorable settlement with the IRS; and • the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA. Our estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current Income taxes payable (approximately $750 million ) and the remaining liability is reported in noncurrent Other taxes payable in our consolidated balance sheet as of September 29, 2019 . The first installment of $750 million was paid in April 2019. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately $1.4 billion , representing tax and interest. • With respect to Pfizer, tax years 2011-2015 are currently under audit. Tax years 2016-2019 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2019), Japan (2017-2019), Europe (2011-2019, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2019, primarily reflecting Brazil) and Puerto Rico (2015-2019). C. Tax Provision on Other Comprehensive Loss The following table provides the components of Tax provision on other comprehensive loss : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Foreign currency translation adjustments, net (a) $ 86 $ 14 $ 96 $ 82 Unrealized holding gains on derivative financial instruments, net 31 35 37 39 Reclassification adjustments for (gains)/losses included in net income (3 ) (28 ) (62 ) 36 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — 1 28 7 (24 ) 77 Unrealized holding gains/(losses) on available-for-sale securities, net 2 20 6 (8 ) Reclassification adjustments for (gains)/losses included in net income (1 ) (6 ) 4 (8 ) Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — — — (45 ) 1 14 10 (62 ) Benefit plans: actuarial gains/(losses), net (41 ) 2 (42 ) 27 Reclassification adjustments related to amortization 23 15 41 43 Reclassification adjustments related to settlements, net 9 10 10 25 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — 637 Other (1 ) 11 2 18 (10 ) 38 12 750 Benefit plans: prior service costs and other, net — — — — Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) (33 ) (33 ) Reclassification adjustments related to curtailments of prior service costs and other, net (11 ) (1 ) (11 ) (4 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — (144 ) Other 1 1 1 1 (21 ) (11 ) (43 ) (179 ) Tax provision on other comprehensive loss $ 84 $ 62 $ 50 $ 667 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements–– Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2018 $ (6,075 ) $ 167 $ (68 ) $ (6,027 ) $ 728 $ (11,275 ) Other comprehensive income/(loss) (a) (443 ) (107 ) 68 94 (137 ) (525 ) Balance, September 29, 2019 $ (6,519 ) $ 60 $ — $ (5,933 ) $ 591 $ (11,801 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first nine months of 2019 . As of September 29, 2019 , with respect to derivative financial instruments, the amount of unrealized pre-tax net gains on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately $247 million . The net gains are expected to be offset primarily by net losses from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 29, 2019
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2018 Financial Report: September 29, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 1,035 $ — $ 1,035 $ 1,571 $ — $ 1,571 Equity (a) 19 7 12 29 17 11 1,054 7 1,047 1,600 17 1,583 Classified as available-for-sale debt securities: Government and agency—non-U.S. 2,498 — 2,498 9,609 — 9,609 Corporate and other 1,772 — 1,772 5,482 — 5,482 4,270 — 4,270 15,091 — 15,091 Total short-term investments 5,324 7 5,317 16,691 17 16,674 Other current assets Derivative assets: Interest rate contracts 59 — 59 97 — 97 Foreign exchange contracts 559 — 559 477 — 477 Total other current assets 618 — 618 574 — 574 Long-term investments Equity securities with readily determinable fair values (a) 1,530 1,506 24 1,273 1,243 30 Classified as available-for-sale debt securities: Government and agency—non-U.S. 45 — 45 94 — 94 Corporate and other 363 — 363 397 — 397 408 — 408 491 — 491 Total long-term investments 1,937 1,506 432 1,764 1,243 521 Other noncurrent assets Derivative assets: Interest rate contracts 557 — 557 335 — 335 Foreign exchange contracts 367 — 367 232 — 232 Total other noncurrent assets 924 — 924 566 — 566 Total assets $ 8,803 $ 1,513 $ 7,290 $ 19,595 $ 1,260 $ 18,335 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ — $ — $ — $ 5 $ — $ 5 Foreign exchange contracts 133 — 133 78 — 78 Total other current liabilities 133 — 133 82 — 82 Other noncurrent liabilities Derivative liabilities: Interest rate contracts — — — 378 — 378 Foreign exchange contracts 600 — 600 564 — 564 Total other noncurrent liabilities 600 — 600 942 — 942 Total liabilities $ 733 $ — $ 733 $ 1,024 $ — $ 1,024 (a) As of September 29, 2019 , short-term equity securities of $12 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: September 29, 2019 December 31, 2018 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 36,044 $ 40,873 $ 40,873 $ 32,909 $ 35,260 $ 35,260 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of September 29, 2019 or December 31, 2018 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach. In addition, as of September 29, 2019 and December 31, 2018 , we had long-term receivables whose fair value is based on Level 3 inputs. As of September 29, 2019 and December 31, 2018 , the differences between the estimated fair values and carrying values of these receivables were not significant. Total Short-Term and Long-Term Investments and Equity-Method Investments The following table represents our investments by classification type: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Short-term investments Equity securities with readily determinable fair values (a) $ 1,054 $ 1,600 Available-for-sale debt securities 4,270 15,091 Held-to-maturity debt securities 978 1,003 Total Short-term investments $ 6,302 $ 17,694 Long-term investments Equity securities with readily determinable fair values $ 1,530 $ 1,273 Available-for-sale debt securities 408 491 Held-to-maturity debt securities 43 59 Private equity investments at cost 742 763 Total Long-term investments $ 2,723 $ 2,586 Equity-method investments 15,999 181 Total long-term investments and equity-method investments $ 18,721 $ 2,767 Held-to-maturity cash equivalents $ 217 $ 199 (a) As of September 29, 2019 and December 31, 2018 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. B. Investments At September 29, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at September 29, 2019 and December 31, 2018 is as follows, including, as of September 29, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: September 29, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,538 $ 11 $ (6 ) $ 2,543 $ 2,498 $ 45 $ — $ 2,543 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,140 1 (6 ) 2,135 1,772 360 2 2,135 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 636 — — 636 593 8 35 636 668 — — 668 Government and agency –– non-U.S. 601 — — 601 601 — — 601 592 — — 592 Total debt securities $ 5,916 $ 11 $ (12 ) $ 5,915 $ 5,464 $ 413 $ 38 $ 5,915 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations. The following table presents the net unrealized (gains) and losses for the period that relate to equity securities still held at the reporting date, calculated as follows: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Net gains recognized during the period on investments in equity securities (a ) $ (6 ) $ (85 ) $ (153 ) $ (460 ) Less: Net gains recognized during the period on equity securities sold during the period (3 ) (58 ) (13 ) (105 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ (3 ) $ (27 ) $ (140 ) $ (355 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . C. Short-Term Borrowings Short-term borrowings include: (MILLIONS OF DOLLARS) September 29, December 31, Commercial paper $ 12,914 $ 3,100 Current portion of long-term debt, principal amount 2,423 4,781 Other short-term borrowings, principal amount (a) 1,334 966 Total short-term borrowings, principal amount 16,671 8,847 Net fair value adjustments related to hedging and purchase accounting 7 (5 ) Net unamortized discounts, premiums and debt issuance costs (61 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 16,617 $ 8,831 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E D. Long-Term Debt New Issuances In the first quarter of 2019, we issued the following senior unsecured notes: Principal (MILLIONS OF DOLLARS) Maturity Date As of September 29, 2019 2.800% notes (a) March 11, 2022 $ 500 2.950% notes (a) March 15, 2024 750 3.450% notes (a) March 15, 2029 1,750 3.900% notes (a) March 15, 2039 750 4.000% notes (a) March 15, 2049 1,250 Total long-term debt issued in the first quarter of 2019 (b) $ 5,000 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. (b) The weighted-average effective interest rate for the notes at issuance was 3.57% . Retirements In January 2019, we repurchased all €1.1 billion ( $1.3 billion , at exchange rates on settlement) principal amount outstanding of the 5.75% euro-denominated debt that was due June 2021 before the maturity date at a redemption value of €1.3 billion ( $1.5 billion , at exchange rates on settlement). As a result, in the first quarter of 2019, we recorded a net loss of approximately $138 million , which included the related termination of cross-currency swaps, and is reported in Other (income)/deductions––net in the condensed consolidated statements of income. For additional information, see Note 4 . The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) September 29, December 31, Total long-term debt, principal amount $ 34,602 $ 32,558 Net fair value adjustments related to hedging and purchase accounting 1,614 479 Net unamortized discounts, premiums and debt issuance costs (179 ) (136 ) Other long-term debt 7 7 Total long-term debt, carried at historical proceeds, as adjusted $ 36,044 $ 32,909 Current portion of long-term debt, carried at historical proceeds, as adjusted $ 2,431 $ 4,776 E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. The derivative financial instruments primarily hedge or offset exposures in the U.K. pound, euro, Japanese yen, Chinese renminbi and Swedish krona . As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,807 $ 810 $ 621 $ 22,984 $ 654 $ 586 Interest rate contracts 6,645 616 — 11,145 432 383 1,425 621 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 18,112 116 112 $ 15,154 55 55 Total $ 1,542 $ 733 $ 1,140 $ 1,024 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.6 billion as of September 29, 2019 and $5.8 billion as of December 31, 2018. The following tables provide information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, September 29, September 30, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 131 $ 183 $ 7 $ 198 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 21 39 22 36 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 378 (195 ) — — — — Hedged item (378 ) 195 — — — — Foreign exchange contracts — 1 — — — — Hedged item — (1 ) — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 112 43 — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 43 14 45 21 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 45 8 — — Foreign currency long-term debt (d) — — 79 17 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (77 ) 150 — — — — All other net — — (1 ) — — — $ (77 ) $ 150 $ 429 $ 304 $ 74 $ 256 Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, September 29, September 30, Nine Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 137 $ 147 $ 265 $ (204 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 105 87 108 84 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 1,191 (715 ) — — — — Hedged item (1,191 ) 715 — — — — Foreign exchange contracts — 5 — — — — Hedged item — (5 ) — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 87 191 — — The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness — — 136 41 99 47 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 65 50 — — Foreign currency long-term debt (d) — — 89 111 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (201 ) 156 — — — — All other net — — — 1 — 1 $ (201 ) $ 156 $ 617 $ 629 $ 472 $ (72 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income–– Unrealized holding gains on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net. (c) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $252 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges. The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29 September 30, Cost of sales $ 2,602 $ 2,694 $ 7,611 $ 8,173 Other (income)/deductions—net 319 (414 ) 537 (1,143 ) The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: September 29, 2019 December 31, 2018 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Actively Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Actively Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Long-term investments $ 45 $ — $ — $ 45 $ (1 ) $ — Short-term borrowings, including current portion of long-term debt — — — 1,499 (5 ) — Long-term debt 7,101 557 700 9,952 (45 ) 129 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of September 29, 2019 , the aggregate fair value of these derivative instruments that are in a net liability position was $673 million , for which we have posted collateral of $661 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of September 29, 2019 , we received cash collateral of $1.3 billion from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts that are in a net asset position. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. For additional information on significant customers, see Notes to Consolidated Financial Statements–– Note 18C. Segment, Geographic and Other Revenue Information: Other Revenue Information in Pfizer’s 2018 Financial Report. As of September 29, 2019 , we had amounts due from a well-diversified, high quality group of banks ( $2.7 billion ) from around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7E above.

Inventories

Inventories	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) September 29, December 31, Finished goods $ 2,594 $ 2,262 Work-in-process 4,866 4,701 Raw materials and supplies 762 546 Inventories (a) $ 8,222 $ 7,508 Noncurrent inventories not included above (b) $ 677 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C ). (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : September 29, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 91,212 $ (62,032 ) $ 29,180 $ 89,430 $ (58,895 ) $ 30,535 Brands 922 (733 ) 190 923 (708 ) 215 Licensing agreements and other (a) 1,776 (1,173 ) 603 1,436 (1,140 ) 296 93,910 (63,938 ) 29,972 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,959 5,959 2,171 2,171 Licensing agreements and other (a) , (b) 1,073 1,073 3 3 9,023 9,023 4,165 4,165 Identifiable intangible assets (a), (c) $ 102,933 $ (63,938 ) $ 38,995 $ 95,954 $ (60,743 ) $ 35,211 (a) The increase in the gross carrying amount of I dentifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreement s (see Note 2A ). (b) Reflects acquired licensing agreements for technology in development. (c) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments. Licensing Agreements Licensing agreements for developed technology and licensing agreements for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These intangible assets represent the amortized or unamortized cost associated with the license, where Pfizer has acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements at September 29, 2019 are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: September 29, 2019 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 95 % — 5 % Licensing agreements and other, finite-lived 98 % — 2 % Licensing agreements and other, indefinite-lived 100 % — — Amortization Total amortization expense for finite-lived intangible assets was $1.2 billion for the third quarter of 2019 and $1.3 billion for the third quarter of 2018 , and $3.6 billion for the first nine months of 2019 and $3.7 billion for the first nine months of 2018 . B. Goodwill Prior to 2019, we managed our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we reorganized our commercial operations and our businesses are managed through three different operating segments––Biopharma, Upjohn and through July 31, 2019 , Pfizer’s Consumer Healthcare business (see Note 13 for further information). Our Consumer Healthcare business was classified as held for sale as of December 31, 2018 and therefore, the goodwill attributable to the Pfizer Consumer Healthcare business was not included in the table below (see Note 2B. for further information). Additionally, upon closing of the transaction during the third quarter, we deconsolidated our Consumer Healthcare business and derecognized Consumer Healthcare goodwill. As a result of the reorganization of our commercial operations, our remaining goodwill was required to be reallocated amongst the then new Biopharma and Upjohn operating segments by determining the fair value of each reporting unit under our old and new management structure and the portions being transferred. We completed this re-allocation based on relative fair value in the second quarter of 2019 and have retrospectively presented goodwill according to the new operating structure. The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2018 $ 42,927 $ 10,484 $ 53,411 Additions (a) 5,378 — 5,378 Other (b) (99 ) (24 ) (123 ) Balance, September 29, 2019 $ 48,206 $ 10,460 $ 58,665 (a) Biopharma additions relate to our acquisition of Array (see Note 2A ). (b) Primarily reflects the impact of foreign exchange.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following tables provide the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 31 $ 33 $ 9 $ 10 Interest cost 157 149 12 14 53 52 19 18 Expected return on plan assets (222 ) (259 ) — — (79 ) (89 ) (8 ) (9 ) Amortization of: Actuarial losses 37 30 2 3 20 25 — 2 Prior service credits (1 ) — — — (1 ) (1 ) (43 ) (45 ) Curtailments — 1 — 1 — (4 ) (47 ) (1 ) Settlements 1 38 22 3 12 — (10 ) — Special termination benefits 3 — 5 — — — 1 — $ (25 ) $ (40 ) $ 41 $ 20 $ 37 $ 17 $ (78 ) $ (26 ) Nine Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 94 $ 104 $ 28 $ 29 Interest cost 472 450 37 40 162 160 57 54 Expected return on plan assets (667 ) (783 ) — — (239 ) (274 ) (25 ) (28 ) Amortization of: Actuarial losses 110 90 7 10 61 77 2 5 Prior service costs/(credits) (2 ) 1 (1 ) (1 ) (3 ) (3 ) (132 ) (135 ) Curtailments — 11 — 1 — (4 ) (47 ) (15 ) Settlements 3 84 21 24 12 — (10 ) — Special termination benefits 4 — 14 — — 1 2 — $ (80 ) $ (147 ) $ 78 $ 75 $ 88 $ 61 $ (124 ) $ (89 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the nine months ended September 29, 2019 $ 8 $ 122 $ 158 $ 103 Expected contributions from our general assets during 2019 (a) 11 147 191 143 (a) Contributions expected to be made for 2019 are inclusive of amounts contributed during the nine months ended September 29, 2019 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Common Shareholders The following table provides the detailed calculation of EPS : Three Months Ended Nine Months Ended (IN MILLIONS) September 29, September 30, September 29, September 30, EPS Numerator––Basic Income from continuing operations $ 7,680 $ 4,111 $ 16,625 $ 11,562 Less: Net income attributable to noncontrolling interests 4 8 19 25 Income from continuing operations attributable to Pfizer Inc. 7,676 4,103 16,606 11,537 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 7,676 4,103 16,605 11,536 Discontinued operations––net of tax 4 11 4 10 Net income attributable to Pfizer Inc. common shareholders $ 7,680 $ 4,114 $ 16,609 $ 11,546 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,676 $ 4,103 $ 16,606 $ 11,537 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 4 11 4 10 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,680 $ 4,114 $ 16,609 $ 11,546 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,545 5,875 5,581 5,899 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 104 112 110 99 Weighted-average number of common shares outstanding––Diluted 5,649 5,986 5,690 5,998 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 3 5 2 3 Cash dividends declared per share $ 0.36 $ 0.34 $ 1.08 $ 1.02 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Commi

Contingencies and Certain Commitments	9 Months Ended
	Sep. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see Note 5B. For a discussion of our legal contingencies, see below. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. The Patent Trial and Appeal Board refused to initiate proceedings as to two patents. In June 2018, the Patent Trial and Appeal Board ruled on another patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In March and June 2019, an additional patent was found invalid in separate proceedings by the Patent Trial and Appeal Board. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, the Wyeth Group) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Ltd. (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging a patent covering polymorphic forms of bosutinib, which expires in 2026, and a patent covering methods of treating chronic myelogenous leukemia, which expires in 2025. Sun is also challenging the same patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, the Wyeth Group brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, the Wyeth Group brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia, each of which expire in 2025. In October 2019, we settled the cases against each of Alembic and Sun on terms not material to Pfizer. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent related to the use of Precedex in an intensive care unit setting, which expired in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted patents were invalid. Hospira has appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). In February 2019, a new stay was entered, extending the stay until the outcome of the appeal in the Fresenius case. In December 2017, Gland Pharma Limited (Gland) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Gland in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. The case against Gland has been stayed pending the outcome of the appeal in the Fresenius case. In December 2017, Jiangsu Hengrui Medicine Co., Ltd. (Hengrui) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Hengrui in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. The case against Hengrui has been stayed pending the outcome of the appeal in the Fresenius case. In February 2018, Baxter Healthcare Corporation (Baxter) filed a declaratory judgment action against Hospira in the U.S. District Court for the District of Delaware seeking a declaration of non-infringement of four patents relating to the Precedex premix formulations and their use. One of the patents included in the action related to the use of Precedex in an intensive care unit setting and expired in 2019 and the other three patents expire in 2032. In March 2018, Hospira filed a counterclaim for infringement of the patent that expired in 2019. In November 2018, the case was dismissed by mutual agreement of the parties. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2018, we settled all of our claims against MicroLabs on terms not material to Pfizer. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. (Sun Ltd.) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Ltd., which covers the active ingredient and expires in December 2025. In October 2018, we brought a third patent infringement action against Sun Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering the extended release formulation of tofacitinib, which expires in 2034. In March and April 2019, the actions against Sun Ltd. were dismissed by mutual agreement of the parties. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Also, in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively, Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of which expire in December 2020 and one of which expires in December 2025. In March 2018, we brought another patent infringement action against Prinston in the U.S. District Court for the District of Delaware asserting the infringement and validity of an additional patent, which had been subsequently challenged by Prinston and which expires in December 2025. In May 2018, we settled all of our claims against Breckenridge on terms not material to Pfizer. In January 2019, we settled all of our claims against Prinston on terms not material to Pfizer. In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of two patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Inlyta (axitinib) In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Kerydin (tavaborole) In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary , filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia. Ibrance (palbociclib) In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of two composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Matters Involving Our Collaboration/Licensing Partners Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. In 2018 and 2019, we settled all pending claims against the various generic challengers on terms not material to Pfizer. Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. Actions In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of September 29, 2019 , approximately 46,500 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purcha

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Pfizer’s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and Consumer Healthcare are responsible for their own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2019, certain costs and expenses could not be directly attributed to one of the then new operating segments. As a result, our operating segment results for the third quarter and first nine months of 2018 include allocations, which management believes are reasonable. As described in Note 1A and Note 2B , acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations in 2019. Operating Segments Some additional information about our Biopharma and Upjohn business segments follows: Pfizer Biopharmaceuticals Group Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The new Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into our Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients’ lives. Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone. Select products include: - Prevnar 13/Prevenar 13 - Eliquis - Xeljanz - Enbrel (outside the U.S. and Canada) Chantix/Champix - Sutent - Xtandi Select products include: - Lyrica - Celebrex - Viagra - Certain generic medicines On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. For additional information, see Note 1A . On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. See Note 1A and Note 2B for additional information. Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines. • GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies. • Other––the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. • Corporate and Other Unallocated––the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $170 billion as of September 29, 2019 and $159 billion as of December 31, 2018 . Selected Income Statement Information As described in Note 1A and Note 2B , acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations in 2019. The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 10,108 $ 9,422 $ 6,503 $ 6,206 Upjohn 2,195 3,036 1,353 2,051 Total reportable segments 12,303 12,458 7,856 8,257 Other business activities — — (1,443 ) (1,298 ) Reconciling Items: Corporate and other unallocated 377 839 (1,431 ) (1,658 ) Purchase accounting adjustments — — (1,141 ) (1,309 ) Acquisition-related costs — — (300 ) (112 ) Certain significant items (b) — — 7,187 298 $ 12,680 $ 13,298 $ 10,727 $ 4,177 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 28,887 $ 27,737 $ 18,484 $ 17,987 Upjohn 8,077 9,302 5,577 6,442 Total reportable segments 36,964 37,040 24,062 24,428 Other business activities — — (3,750 ) (3,605 ) Reconciling Items: Corporate and other unallocated 2,098 2,631 (4,108 ) (4,558 ) Purchase accounting adjustments — — (3,357 ) (3,665 ) Acquisition-related costs — — (152 ) (221 ) Certain significant items (b) — — 6,495 452 $ 39,062 $ 39,670 $ 19,190 $ 12,831 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018 , and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million , (ii) charges for certain legal matters of $63 million , (iii) charges for business and legal entity alignment of $89 million , (iv) net gains recognized during the period on investments in equity securities of $3 million , (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B , Note 3 and Note 4. For Earnings in the third quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million , (ii) net charges for certain legal matters of $37 million , (iii) charges for business and legal entity alignment of $1 million , (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million , (ii) charges for certain legal matters of $72 million , (iii) certain asset impairment charges of $149 million , (iv) charges for business and legal entity alignment of $353 million , (v) net gains recognized during the period on investments in equity securities of $139 million , (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion , (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million , (ii) net credits for certain legal matters of $70 million , (iii) certain asset impairment charges of $31 million , (iv) charges for business and legal entity alignment of $5 million , (v) net gains recognized during the period on investments in equity securities of $460 million , (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information As described in Note 1A and Note 2B , acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations in 2019. The following table provides revenues by geographic area: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, % Change September 29, September 30, % Change U.S. $ 5,850 $ 6,361 (8 ) $ 18,360 $ 18,861 (3 ) Developed Europe (a) 2,135 2,231 (4 ) 6,450 6,657 (3 ) Developed Rest of World (b) 1,585 1,640 (3 ) 4,758 4,795 (1 ) Emerging Markets (c) 3,110 3,066 1 9,493 9,358 1 Revenues $ 12,680 $ 13,298 (5 ) $ 39,062 $ 39,670 (2 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the third quarter of 2019 and $1.8 billion in the third quarter of 2018 , and were $5.2 billion in the first nine months of 2019 and $5.3 billion in the first nine months of 2018 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey. C. Other Revenue Information Significant Product Revenues As described in Note 1A and Note 2B , acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations in 2019. The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS September 29, September 30, September 29, September 30, TOTAL REVENUES $ 12,680 $ 13,298 $ 39,062 $ 39,670 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a) $ 10,108 $ 9,422 $ 28,887 $ 27,737 Internal Medicine (b) $ 2,207 $ 2,182 $ 6,754 $ 6,529 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,025 870 3,121 2,524 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 276 261 825 789 Premarin family Symptoms of menopause 182 204 542 605 BMP2 Development of bone and cartilage 66 54 212 206 Toviaz Overactive bladder 61 67 186 197 All other Internal Medicine Various 597 727 1,867 2,208 Oncology (c) $ 2,350 $ 1,840 $ 6,547 $ 5,487 Ibrance Advanced breast cancer 1,283 1,025 3,677 2,985 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 224 248 704 785 Xtandi alliance revenues Castration-resistant prostate cancer 225 180 594 510 Xalkori ALK-positive and ROS1-positive advanced NSCLC 130 127 385 417 Inlyta Advanced RCC 139 71 316 226 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 90 69 267 206 Retacrit (j) Anemia 64 19 147 55 All other Oncology Various 194 101 456 302 Hospital (d) $ 1,917 $ 1,841 $ 5,717 $ 5,944 Sulperazon Treatment of infections 163 145 505 464 Medrol (e) Steroid anti-inflammatory 109 110 348 369 Vfend Fungal infections 87 87 265 294 Zithromax (e) Bacterial infections 77 61 254 243 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 92 68 238 215 Zyvox Bacterial infections 61 50 195 184 Fragmin Slows blood clotting 62 76 185 221 Zosyn/Tazocin Antibiotic 49 56 153 176 Tygacil Tetracycline class antibiotic 50 60 146 186 Pfizer CentreOne (f) Various 176 159 556 539 All other Anti-infectives Various 335 300 961 929 All other Hospital (d) Various 656 669 1,910 2,124 Vaccines $ 1,808 $ 1,845 $ 4,795 $ 4,708 Prevnar 13/Prevenar 13 Pneumococcal disease 1,603 1,660 4,268 4,290 FSME/IMMUN-TicoVac Tick-borne encephalitis disease 64 57 197 162 Nimenrix Meningococcal disease 52 46 159 95 Trumenba Meningococcal disease 73 61 117 95 All other Vaccines Various 16 21 54 65 Inflammation & Immunology (I&I) (g) $ 1,226 $ 1,184 $ 3,482 $ 3,419 Xeljanz RA, PsA, UC 599 432 1,634 1,221 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 415 531 1,285 1,589 Inflectra/Remsima (g), (j) Inflammatory diseases 155 166 446 469 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 43 40 92 104 All other I&I Various 15 14 24 36 (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS September 29, September 30, September 29, September 30, Rare Disease $ 601 $ 531 $ 1,592 $ 1,651 BeneFIX Hemophilia 125 132 372 420 Genotropin Replacement of human growth hormone 124 143 357 416 Refacto AF/Xyntha Hemophilia 104 117 319 388 Vyndaqel ATTR-Cardiomyopathy and Polyneuropathy 156 37 259 108 Somavert Acromegaly 64 64 192 195 All other Rare Disease Various 28 38 94 123 UPJOHN (b) , (h) $ 2,195 $ 3,036 $ 8,077 $ 9,302 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 527 1,213 2,888 3,649 Lipitor Reduction of LDL cholesterol 476 507 1,506 1,539 Norvasc Hypertension 219 248 735 777 Celebrex Arthritis pain and inflammation, acute pain 179 188 526 494 Viagra Erectile dysfunction 120 137 379 509 Effexor Depression and certain anxiety disorders 80 78 242 228 Zoloft Depression and certain anxiety disorders 74 72 217 223 Xalatan/Xalacom Glaucoma and ocular hypertension 68 76 201 233 Xanax Anxiety disorders 50 52 147 163 Revatio Pulmonary arterial hypertension 24 53 122 163 All other Upjohn Various 379 411 1,114 1,325 CONSUMER HEALTHCARE BUSINESS (i) $ 377 $ 839 $ 2,098 $ 2,631 Total Alliance revenues Various $ 1,141 $ 977 $ 3,418 $ 2,820 Total Biosimilars (j) Various $ 236 $ 197 $ 632 $ 558 Total Sterile Injectable Pharmaceuticals (k) $ 1,248 $ 1,239 $ 3,703 $ 3,928 (a) The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Disease. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) . (b) We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation. (c) We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation. (d) Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne (f) . All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (e) 2018 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category. (f) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation. (h) Pfizer’s Upjohn business encompasses primarily off-patent branded and generic medicines that includes a portfolio of 20 globally recognized solid oral dose brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone. (i) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 1A and Note 2B . (j) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (k) Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 25, 2019 and August 26, 2018 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended September 29, 2019 and September 30, 2018 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2018 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . In addition, certain amounts within Long-term investments in the December 31, 2018 condensed consolidated balance sheet have been reclassified to Equity-method investments to conform to the current presentation. For additional information, see Note 2B. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Adoption of New Accounting Standards	Adoption of New Accounting Standards On January 1, 2019, we adopted four new accounting standards. Leases ––On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of $1.4 billion and current and noncurrent operating lease liabilities of $1.4 billion as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $30 million on a pre-tax basis ( $20 million after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules. Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574 Adoption of the standard related to leases did not have a material impact on our condensed consolidated statements of income or condensed consolidated statements of cash flows for the nine months ended September 29, 2019 . For additional information, see Note 1D . Amortization Period for Certain Callable Debt Securities Held at a Premium ––We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features ––We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Share-Based Payments to Nonemployees ––We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2018, we adopted eleven new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 included in our 2018 Financial Report. C. Revenues and Trade Accounts Receivable Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.6 billion as of September 29, 2019 and $5.4 billion as of December 31, 2018 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) September 29, December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,203 $ 1,288 Other current liabilities : Accrued rebates 3,275 3,208 Other accruals 617 531 Other noncurrent liabilities 463 399 Total accrued rebates and other accruals $ 5,557 $ 5,426 D. Leases On January 1, 2019, we adopted a new accounting standard for leases. For further information, see Note 1B . We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $74 million for the three months ended September 29, 2019 and $192 million for the nine months ended September 29, 2019 . We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes. We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: Balance at (MILLIONS OF DOLLARS) Balance Sheet Classification September 29, ROU assets Other noncurrent assets $ 1,306 Lease liabilities (short-term) Other current liabilities 281 Lease liabilities (long-term) Other noncurrent liabilities 1,037 Our total lease costs are as follows: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, 2019 September 29, 2019 Operating lease cost $ 111 $ 310 Variable lease cost 74 192 Sublease income (10 ) (31 ) Total lease cost $ 174 $ 471 Other supplemental information includes the following: Weighted-Average Remaining Contractual Lease Term (Years) as of Weighted-Average Discount Rate as of (MILLIONS OF DOLLARS) September 29, September 29, Nine Months Ended September 29, 2019 Operating leases 6.8 3.6 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 244 (Gains)/losses on sale and leaseback transactions, net (32 ) ROU assets obtained in exchange for new operating lease liabilities $ 250 The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of September 29, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 322 1-2 years 279 2-3 years 222 3-4 years 176 4-5 years 110 Thereafter 406 Total undiscounted lease payments 1,516 Less: Imputed interest 197 Present Value of Minimum Lease Payments 1,319 Less: Current portion 281 Noncurrent portion $ 1,037 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date. In April 2018, we entered an agreement to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this 20 -year lease is approximately $1.7 billion . Prior to our adoption of the new lease standard, rental expense, net of sublease income, was $301 million in 2018, $314 million in 2017 and $292 million in 2016. As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Impact of Adoption of Lease Accounting Standard Updates on Consolidated Balance Sheet	Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574
Schedule of Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) September 29, December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,203 $ 1,288 Other current liabilities : Accrued rebates 3,275 3,208 Other accruals 617 531 Other noncurrent liabilities 463 399 Total accrued rebates and other accruals $ 5,557 $ 5,426
ROU Assets and Liabilities Presented in Condensed Consolidated Balance Sheets	For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: Balance at (MILLIONS OF DOLLARS) Balance Sheet Classification September 29, ROU assets Other noncurrent assets $ 1,306 Lease liabilities (short-term) Other current liabilities 281 Lease liabilities (long-term) Other noncurrent liabilities 1,037
Total Lease Costs and Other Supplemental Information	Our total lease costs are as follows: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, 2019 September 29, 2019 Operating lease cost $ 111 $ 310 Variable lease cost 74 192 Sublease income (10 ) (31 ) Total lease cost $ 174 $ 471 Other supplemental information includes the following: Weighted-Average Remaining Contractual Lease Term (Years) as of Weighted-Average Discount Rate as of (MILLIONS OF DOLLARS) September 29, September 29, Nine Months Ended September 29, 2019 Operating leases 6.8 3.6 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 244 (Gains)/losses on sale and leaseback transactions, net (32 ) ROU assets obtained in exchange for new operating lease liabilities $ 250
Schedule of Future Minimum Rental Payments for Operating Leases	The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of September 29, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 322 1-2 years 279 2-3 years 222 3-4 years 176 4-5 years 110 Thereafter 406 Total undiscounted lease payments 1,516 Less: Imputed interest 197 Present Value of Minimum Lease Payments 1,319 Less: Current portion 281 Noncurrent portion $ 1,037 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date.
Schedule of Future Minimum Rental Payments for Operating Leases	As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Acquisitions, Equity-Method I_2

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement (Tables)	9 Months Ended
	Sep. 29, 2019
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Schedule of Amounts Associated with the Consumer Healthcare Business	The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following: (MILLIONS OF DOLLARS) December 31, Assets Held for Sale Cash and cash equivalents $ 32 Trade accounts receivable, less allowance for doubtful accounts 532 Inventories 538 Other current assets 56 PP&E 675 Identifiable intangible assets, less accumulated amortization 5,763 Goodwill 1,972 Noncurrent deferred tax assets and other noncurrent tax assets 54 Other noncurrent assets 57 Total Consumer Healthcare assets held for sale 9,678 Other assets held for sale (a) 46 Assets held for sale $ 9,725 Liabilities Held for Sale Trade accounts payable $ 406 Income taxes payable 39 Accrued compensation and related items 93 Other current liabilities 353 Pension benefit obligations, net 39 Postretirement benefit obligations, net 33 Noncurrent deferred tax liabilities 870 Other noncurrent liabilities 56 Total Consumer Healthcare liabilities held for sale $ 1,890 (a) Other assets held for sale consist of PP&E.

Restructuring Charges and Oth_2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Restructuring charges/(credits): Employee terminations $ 82 $ (24 ) $ (86 ) $ (53 ) Asset impairments 3 12 3 8 Exit costs/(credits) (1 ) 14 33 14 Restructuring charges/(credits) (a) 83 1 (50 ) (32 ) Transaction costs (b) 65 1 65 1 Integration costs and other (c) 217 82 281 202 Restructuring charges and certain acquisition-related costs 365 85 295 172 Net periodic benefit costs recorded in Other (income)/deductions––net 9 41 19 103 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 6 12 21 43 Selling, informational and administrative expenses — — 2 — Research and development expenses — — 6 — Total additional depreciation––asset restructuring 6 12 29 43 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 14 21 45 57 Selling, informational and administrative expenses 23 17 48 51 Research and development expenses 3 9 16 22 Total implementation costs 40 48 109 130 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 420 $ 186 $ 452 $ 447 (a) In the third quarter of 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives as well as our acquisition of Array. In the first nine months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Note 5B ), partially offset by employee termination costs associated with cost-reduction and productivity initiatives, as well as our acquisition of Array. In the third quarter of 2018, restructuring charges were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs. In the first nine months of 2018, restructuring credits were mostly related to the reversal of previously recorded accruals for employee termination costs. The restructuring activities for 2019 are associated with the following: • For the third quarter of 2019 , Biopharma ( $10 million charge ); Upjohn ( $6 million credit ); and Other ( $79 million charge). • For the first nine months of 2019 , Biopharma ( $38 million credit); Upjohn ( $27 million credit ); and Other ( $15 million charge). The restructuring activities for 2018 are associated with the following: • For the third quarter of 2018, total reportable segments ( $6 million credit); and Other ( $7 million charge). • For the first nine months of 2018, total reportable segments ( $30 million credit); and Other ( $2 million credit). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments. (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. In the third quarter and first nine months of 2019, transaction costs relate to our acquisition of Array. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the third quarter and first nine months of 2019, integration costs and other primarily includes $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see Note 2A ). In the third quarter and first nine months of 2018, integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2018 (a) $ 1,203 $ — $ 49 $ 1,252 Provision/(credit) (b) (86 ) 3 33 (50 ) Utilization and other (c) (431 ) (3 ) (33 ) (467 ) Balance, September 29, 2019 (d) $ 686 $ — $ 48 $ 734 (a) Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ). (b) Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Note 5B for additional information. (c) Includes adjustments for foreign currency translation. (d) Included in Other current liabilities ( $535 million ) and Other noncurrent liabilities ( $199 million ).

Other (Income)_Deductions - N_2

Other (Income)/Deductions - Net (Tables)	9 Months Ended
	Sep. 29, 2019
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Interest income (a) $ (60 ) $ (82 ) (185 ) (240 ) Interest expense (a) 409 310 1,158 946 Net interest expense 348 228 973 706 Royalty-related income (b) (155 ) (143 ) (475 ) (360 ) Net gains on asset disposals (32 ) (4 ) (33 ) (19 ) Net gains recognized during the period on investments in equity securities (c) (6 ) (85 ) (153 ) (460 ) Net realized losses on sales of investments in debt securities — 8 — 19 Income from collaborations, out-licensing arrangements and sales of compound/product rights (d) (20 ) (139 ) (124 ) (455 ) Net periodic benefit credits other than service costs (e) (19 ) (65 ) (110 ) (231 ) Certain legal matters, net (f) 64 37 84 (70 ) Certain asset impairments (g) 28 (1 ) 188 40 Business and legal entity alignment costs (h) 87 1 343 5 Net losses on early retirement of debt (i) — — 138 3 Other, net (j) 24 (252 ) (294 ) (322 ) Other (income)/deductions––net $ 319 $ (414 ) $ 537 $ (1,143 ) (a) Interest income decreased in the third quarter and first nine months of 2019 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2019 , mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year periods. (b) The increase in royalty-related income for the first nine months of 2019 is primarily due to a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million . (c) The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B . (d) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first nine months of 2019 , mainly includes, among other things, $70 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® (fluticasone propionate and salmeterol inhalation powder) and $26 million in milestone income from multiple licensees. In the third quarter of 2018 , primarily included, among other things, (i) $40 million in milestone income from a certain licensee, (ii) a $35 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of Crohn’s disease and (iii) $45 million in gains related to sales of compound/product rights. In the first nine months of 2018 , mainly included, among other things, (i) approximately $128 million in milestone income from multiple licensees, (ii) an upfront payment to us of $75 million for the sale of an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator for cognitive impairment associated with schizophrenia (CIAS) to Biogen Inc., (iii) $110 million in milestone payments received from Shire, of which $75 million was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis and $35 million was received from Shire related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn’s disease, (iv) a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU and (v) $45 million in gains related to sales of compound/product rights. (e) For additional information, see Note 10 . (f) For the first nine months of 2018 , the net credits primarily represented the reversal of a legal accrual where a loss was no longer deemed probable. (g) The first nine months of 2019 include an intangible asset impairment charge of $10 million and the first nine months of 2018 included an intangible asset impairment charge of $31 million recorded in the second quarter of 2018, which are all related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflect , among other things, updated commercial forecasts. The first nine months of 2019 also includes intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first nine months of 2019 , includes other asset impairments of $48 million . (h) In the third quarter and first nine months of 2019, and in the third quarter of 2018, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first nine months of 2018, mainly represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In the first nine months of 2019 , represents net losses due to the early retirement of debt in the first quarter of 2019, inclusive of the related termination of cross-currency swaps. (j) The third quarter of 2019 includes, among other things, dividend income of $43 million from our investment in ViiV and charges of $121 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. The first nine months of 2019 includes, among other things, (i) dividend income of $184 million from our investment in ViiV, (ii) charges of $146 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) $50 million of income from insurance recoveries related to Hurricane Maria. The third quarter and first nine months of 2018 included a non-cash $343 million pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. The third quarter of 2018 also included, among other things, dividend income of $91 million from our investment in ViiV, and charges of $122 million , reflecting the change in the fair value of contingent consideration. The first nine months of 2018 also included, among other things, (i) dividend income of $226 million from our investment in ViiV, (ii) charges of $257 million , reflecting the change in the fair value of contingent consideration, (iii) a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T development program assets obtained from Cellectis S.A. and Les Laboratoires Servier SAS in connection with our contribution agreement entered into with Allogene, and (iv) a non-cash $17 million gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg.
Schedule of Additional Information About Intangible Assets Impaired	The following table provides additional information about the intangible assets that were impaired during 2019 in Other (income)/deductions: Fair Value (a) Nine Months Ended September 29, 2019 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ — $ — $ — $ — $ 90 Intangible assets––Developed technology rights (b) 13 — — 13 50 Total $ 13 $ — $ — $ 13 $ 140 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the first nine months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision on other comprehensive loss : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Foreign currency translation adjustments, net (a) $ 86 $ 14 $ 96 $ 82 Unrealized holding gains on derivative financial instruments, net 31 35 37 39 Reclassification adjustments for (gains)/losses included in net income (3 ) (28 ) (62 ) 36 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — 1 28 7 (24 ) 77 Unrealized holding gains/(losses) on available-for-sale securities, net 2 20 6 (8 ) Reclassification adjustments for (gains)/losses included in net income (1 ) (6 ) 4 (8 ) Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — — — (45 ) 1 14 10 (62 ) Benefit plans: actuarial gains/(losses), net (41 ) 2 (42 ) 27 Reclassification adjustments related to amortization 23 15 41 43 Reclassification adjustments related to settlements, net 9 10 10 25 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — 637 Other (1 ) 11 2 18 (10 ) 38 12 750 Benefit plans: prior service costs and other, net — — — — Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) (33 ) (33 ) Reclassification adjustments related to curtailments of prior service costs and other, net (11 ) (1 ) (11 ) (4 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — — (144 ) Other 1 1 1 1 (21 ) (11 ) (43 ) (179 ) Tax provision on other comprehensive loss $ 84 $ 62 $ 50 $ 667 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements–– Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2018 $ (6,075 ) $ 167 $ (68 ) $ (6,027 ) $ 728 $ (11,275 ) Other comprehensive income/(loss) (a) (443 ) (107 ) 68 94 (137 ) (525 ) Balance, September 29, 2019 $ (6,519 ) $ 60 $ — $ (5,933 ) $ 591 $ (11,801 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first nine months of 2019 .

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 29, 2019
Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2018 Financial Report: September 29, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 1,035 $ — $ 1,035 $ 1,571 $ — $ 1,571 Equity (a) 19 7 12 29 17 11 1,054 7 1,047 1,600 17 1,583 Classified as available-for-sale debt securities: Government and agency—non-U.S. 2,498 — 2,498 9,609 — 9,609 Corporate and other 1,772 — 1,772 5,482 — 5,482 4,270 — 4,270 15,091 — 15,091 Total short-term investments 5,324 7 5,317 16,691 17 16,674 Other current assets Derivative assets: Interest rate contracts 59 — 59 97 — 97 Foreign exchange contracts 559 — 559 477 — 477 Total other current assets 618 — 618 574 — 574 Long-term investments Equity securities with readily determinable fair values (a) 1,530 1,506 24 1,273 1,243 30 Classified as available-for-sale debt securities: Government and agency—non-U.S. 45 — 45 94 — 94 Corporate and other 363 — 363 397 — 397 408 — 408 491 — 491 Total long-term investments 1,937 1,506 432 1,764 1,243 521 Other noncurrent assets Derivative assets: Interest rate contracts 557 — 557 335 — 335 Foreign exchange contracts 367 — 367 232 — 232 Total other noncurrent assets 924 — 924 566 — 566 Total assets $ 8,803 $ 1,513 $ 7,290 $ 19,595 $ 1,260 $ 18,335 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ — $ — $ — $ 5 $ — $ 5 Foreign exchange contracts 133 — 133 78 — 78 Total other current liabilities 133 — 133 82 — 82 Other noncurrent liabilities Derivative liabilities: Interest rate contracts — — — 378 — 378 Foreign exchange contracts 600 — 600 564 — 564 Total other noncurrent liabilities 600 — 600 942 — 942 Total liabilities $ 733 $ — $ 733 $ 1,024 $ — $ 1,024 (a) As of September 29, 2019 , short-term equity securities of $12 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: September 29, 2019 December 31, 2018 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 36,044 $ 40,873 $ 40,873 $ 32,909 $ 35,260 $ 35,260
Investments by Classification Type	The following table represents our investments by classification type: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Short-term investments Equity securities with readily determinable fair values (a) $ 1,054 $ 1,600 Available-for-sale debt securities 4,270 15,091 Held-to-maturity debt securities 978 1,003 Total Short-term investments $ 6,302 $ 17,694 Long-term investments Equity securities with readily determinable fair values $ 1,530 $ 1,273 Available-for-sale debt securities 408 491 Held-to-maturity debt securities 43 59 Private equity investments at cost 742 763 Total Long-term investments $ 2,723 $ 2,586 Equity-method investments 15,999 181 Total long-term investments and equity-method investments $ 18,721 $ 2,767 Held-to-maturity cash equivalents $ 217 $ 199 (a) As of September 29, 2019 and December 31, 2018 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
Schedule of Held-to-maturity Securities	At September 29, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at September 29, 2019 and December 31, 2018 is as follows, including, as of September 29, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: September 29, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,538 $ 11 $ (6 ) $ 2,543 $ 2,498 $ 45 $ — $ 2,543 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,140 1 (6 ) 2,135 1,772 360 2 2,135 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 636 — — 636 593 8 35 636 668 — — 668 Government and agency –– non-U.S. 601 — — 601 601 — — 601 592 — — 592 Total debt securities $ 5,916 $ 11 $ (12 ) $ 5,915 $ 5,464 $ 413 $ 38 $ 5,915 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Schedule of Available-for-sale Securities	At September 29, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at September 29, 2019 and December 31, 2018 is as follows, including, as of September 29, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: September 29, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,538 $ 11 $ (6 ) $ 2,543 $ 2,498 $ 45 $ — $ 2,543 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,140 1 (6 ) 2,135 1,772 360 2 2,135 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 636 — — 636 593 8 35 636 668 — — 668 Government and agency –– non-U.S. 601 — — 601 601 — — 601 592 — — 592 Total debt securities $ 5,916 $ 11 $ (12 ) $ 5,915 $ 5,464 $ 413 $ 38 $ 5,915 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At September 29, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at September 29, 2019 and December 31, 2018 is as follows, including, as of September 29, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: September 29, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,538 $ 11 $ (6 ) $ 2,543 $ 2,498 $ 45 $ — $ 2,543 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,140 1 (6 ) 2,135 1,772 360 2 2,135 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 636 — — 636 593 8 35 636 668 — — 668 Government and agency –– non-U.S. 601 — — 601 601 — — 601 592 — — 592 Total debt securities $ 5,916 $ 11 $ (12 ) $ 5,915 $ 5,464 $ 413 $ 38 $ 5,915 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Schedule of Gains and Losses on Investment Securities	The following table presents the net unrealized (gains) and losses for the period that relate to equity securities still held at the reporting date, calculated as follows: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Net gains recognized during the period on investments in equity securities (a ) $ (6 ) $ (85 ) $ (153 ) $ (460 ) Less: Net gains recognized during the period on equity securities sold during the period (3 ) (58 ) (13 ) (105 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ (3 ) $ (27 ) $ (140 ) $ (355 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS OF DOLLARS) September 29, December 31, Commercial paper $ 12,914 $ 3,100 Current portion of long-term debt, principal amount 2,423 4,781 Other short-term borrowings, principal amount (a) 1,334 966 Total short-term borrowings, principal amount 16,671 8,847 Net fair value adjustments related to hedging and purchase accounting 7 (5 ) Net unamortized discounts, premiums and debt issuance costs (61 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 16,617 $ 8,831 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) September 29, December 31, Total long-term debt, principal amount $ 34,602 $ 32,558 Net fair value adjustments related to hedging and purchase accounting 1,614 479 Net unamortized discounts, premiums and debt issuance costs (179 ) (136 ) Other long-term debt 7 7 Total long-term debt, carried at historical proceeds, as adjusted $ 36,044 $ 32,909 Current portion of long-term debt, carried at historical proceeds, as adjusted $ 2,431 $ 4,776 In the first quarter of 2019, we issued the following senior unsecured notes: Principal (MILLIONS OF DOLLARS) Maturity Date As of September 29, 2019 2.800% notes (a) March 11, 2022 $ 500 2.950% notes (a) March 15, 2024 750 3.450% notes (a) March 15, 2029 1,750 3.900% notes (a) March 15, 2039 750 4.000% notes (a) March 15, 2049 1,250 Total long-term debt issued in the first quarter of 2019 (b) $ 5,000 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. (b) The weighted-average effective interest rate for the notes at issuance was 3.57% .
Schedule of Derivative Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,807 $ 810 $ 621 $ 22,984 $ 654 $ 586 Interest rate contracts 6,645 616 — 11,145 432 383 1,425 621 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 18,112 116 112 $ 15,154 55 55 Total $ 1,542 $ 733 $ 1,140 $ 1,024 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.6 billion as of September 29, 2019 and $5.8 billion as of December 31, 2018.
Schedule of Derivative Assets	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,807 $ 810 $ 621 $ 22,984 $ 654 $ 586 Interest rate contracts 6,645 616 — 11,145 432 383 1,425 621 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 18,112 116 112 $ 15,154 55 55 Total $ 1,542 $ 733 $ 1,140 $ 1,024 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.6 billion as of September 29, 2019 and $5.8 billion as of December 31, 2018.
Schedule of Derivative Liabilities	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) September 29, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,807 $ 810 $ 621 $ 22,984 $ 654 $ 586 Interest rate contracts 6,645 616 — 11,145 432 383 1,425 621 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 18,112 116 112 $ 15,154 55 55 Total $ 1,542 $ 733 $ 1,140 $ 1,024 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.6 billion as of September 29, 2019 and $5.8 billion as of December 31, 2018.
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following tables provide information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, September 29, September 30, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 131 $ 183 $ 7 $ 198 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 21 39 22 36 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 378 (195 ) — — — — Hedged item (378 ) 195 — — — — Foreign exchange contracts — 1 — — — — Hedged item — (1 ) — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 112 43 — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 43 14 45 21 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 45 8 — — Foreign currency long-term debt (d) — — 79 17 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (77 ) 150 — — — — All other net — — (1 ) — — — $ (77 ) $ 150 $ 429 $ 304 $ 74 $ 256 Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, September 29, September 30, Nine Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 137 $ 147 $ 265 $ (204 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 105 87 108 84 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 1,191 (715 ) — — — — Hedged item (1,191 ) 715 — — — — Foreign exchange contracts — 5 — — — — Hedged item — (5 ) — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 87 191 — — The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness — — 136 41 99 47 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 65 50 — — Foreign currency long-term debt (d) — — 89 111 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (201 ) 156 — — — — All other net — — — 1 — 1 $ (201 ) $ 156 $ 617 $ 629 $ 472 $ (72 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income–– Unrealized holding gains on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net. (c) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $252 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges.
Schedule of Total Amount of Each Income and Expense Line in which Results of Cash Flow Hedges are Recorded	The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29 September 30, Cost of sales $ 2,602 $ 2,694 $ 7,611 $ 8,173 Other (income)/deductions—net 319 (414 ) 537 (1,143 )
Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded	The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: September 29, 2019 December 31, 2018 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Actively Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Actively Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Long-term investments $ 45 $ — $ — $ 45 $ (1 ) $ — Short-term borrowings, including current portion of long-term debt — — — 1,499 (5 ) — Long-term debt 7,101 557 700 9,952 (45 ) 129 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments. The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29 September 30, Cost of sales $ 2,602 $ 2,694 $ 7,611 $ 8,173 Other (income)/deductions—net 319 (414 ) 537 (1,143 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) September 29, December 31, Finished goods $ 2,594 $ 2,262 Work-in-process 4,866 4,701 Raw materials and supplies 762 546 Inventories (a) $ 8,222 $ 7,508 Noncurrent inventories not included above (b) $ 677 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C ). (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) September 29, December 31, Finished goods $ 2,594 $ 2,262 Work-in-process 4,866 4,701 Raw materials and supplies 762 546 Inventories (a) $ 8,222 $ 7,508 Noncurrent inventories not included above (b) $ 677 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C ). (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_2

Identifiable Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : September 29, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 91,212 $ (62,032 ) $ 29,180 $ 89,430 $ (58,895 ) $ 30,535 Brands 922 (733 ) 190 923 (708 ) 215 Licensing agreements and other (a) 1,776 (1,173 ) 603 1,436 (1,140 ) 296 93,910 (63,938 ) 29,972 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,959 5,959 2,171 2,171 Licensing agreements and other (a) , (b) 1,073 1,073 3 3 9,023 9,023 4,165 4,165 Identifiable intangible assets (a), (c) $ 102,933 $ (63,938 ) $ 38,995 $ 95,954 $ (60,743 ) $ 35,211 (a) The increase in the gross carrying amount of I dentifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreement s (see Note 2A ). (b) Reflects acquired licensing agreements for technology in development. (c) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments.
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : September 29, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 91,212 $ (62,032 ) $ 29,180 $ 89,430 $ (58,895 ) $ 30,535 Brands 922 (733 ) 190 923 (708 ) 215 Licensing agreements and other (a) 1,776 (1,173 ) 603 1,436 (1,140 ) 296 93,910 (63,938 ) 29,972 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,959 5,959 2,171 2,171 Licensing agreements and other (a) , (b) 1,073 1,073 3 3 9,023 9,023 4,165 4,165 Identifiable intangible assets (a), (c) $ 102,933 $ (63,938 ) $ 38,995 $ 95,954 $ (60,743 ) $ 35,211 (a) The increase in the gross carrying amount of I dentifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreement s (see Note 2A ). (b) Reflects acquired licensing agreements for technology in development. (c) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments.
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: September 29, 2019 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 95 % — 5 % Licensing agreements and other, finite-lived 98 % — 2 % Licensing agreements and other, indefinite-lived 100 % — —
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2018 $ 42,927 $ 10,484 $ 53,411 Additions (a) 5,378 — 5,378 Other (b) (99 ) (24 ) (123 ) Balance, September 29, 2019 $ 48,206 $ 10,460 $ 58,665 (a) Biopharma additions relate to our acquisition of Array (see Note 2A ). (b) Primarily reflects the impact of foreign exchange.

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following tables provide the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 31 $ 33 $ 9 $ 10 Interest cost 157 149 12 14 53 52 19 18 Expected return on plan assets (222 ) (259 ) — — (79 ) (89 ) (8 ) (9 ) Amortization of: Actuarial losses 37 30 2 3 20 25 — 2 Prior service credits (1 ) — — — (1 ) (1 ) (43 ) (45 ) Curtailments — 1 — 1 — (4 ) (47 ) (1 ) Settlements 1 38 22 3 12 — (10 ) — Special termination benefits 3 — 5 — — — 1 — $ (25 ) $ (40 ) $ 41 $ 20 $ 37 $ 17 $ (78 ) $ (26 ) Nine Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Sept. 29, Sept. 30, Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 94 $ 104 $ 28 $ 29 Interest cost 472 450 37 40 162 160 57 54 Expected return on plan assets (667 ) (783 ) — — (239 ) (274 ) (25 ) (28 ) Amortization of: Actuarial losses 110 90 7 10 61 77 2 5 Prior service costs/(credits) (2 ) 1 (1 ) (1 ) (3 ) (3 ) (132 ) (135 ) Curtailments — 11 — 1 — (4 ) (47 ) (15 ) Settlements 3 84 21 24 12 — (10 ) — Special termination benefits 4 — 14 — — 1 2 — $ (80 ) $ (147 ) $ 78 $ 75 $ 88 $ 61 $ (124 ) $ (89 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the nine months ended September 29, 2019 $ 8 $ 122 $ 158 $ 103 Expected contributions from our general assets during 2019 (a) 11 147 191 143
Schedule of Employer Contributions to Pension and Postretirement Plans	The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the nine months ended September 29, 2019 $ 8 $ 122 $ 158 $ 103 Expected contributions from our general assets during 2019 (a) 11 147 191 143 (a) Contributions expected to be made for 2019 are inclusive of amounts contributed during the nine months ended September 29, 2019 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att_2

Earnings Per Common Share Attributable to Common Shareholders (Tables)	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of EPS : Three Months Ended Nine Months Ended (IN MILLIONS) September 29, September 30, September 29, September 30, EPS Numerator––Basic Income from continuing operations $ 7,680 $ 4,111 $ 16,625 $ 11,562 Less: Net income attributable to noncontrolling interests 4 8 19 25 Income from continuing operations attributable to Pfizer Inc. 7,676 4,103 16,606 11,537 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 7,676 4,103 16,605 11,536 Discontinued operations––net of tax 4 11 4 10 Net income attributable to Pfizer Inc. common shareholders $ 7,680 $ 4,114 $ 16,609 $ 11,546 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,676 $ 4,103 $ 16,606 $ 11,537 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 4 11 4 10 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,680 $ 4,114 $ 16,609 $ 11,546 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,545 5,875 5,581 5,899 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 104 112 110 99 Weighted-average number of common shares outstanding––Diluted 5,649 5,986 5,690 5,998 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 3 5 2 3 Cash dividends declared per share $ 0.36 $ 0.34 $ 1.08 $ 1.02 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other_2

Segment, Geographic and Other Revenue Information (Tables)	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 10,108 $ 9,422 $ 6,503 $ 6,206 Upjohn 2,195 3,036 1,353 2,051 Total reportable segments 12,303 12,458 7,856 8,257 Other business activities — — (1,443 ) (1,298 ) Reconciling Items: Corporate and other unallocated 377 839 (1,431 ) (1,658 ) Purchase accounting adjustments — — (1,141 ) (1,309 ) Acquisition-related costs — — (300 ) (112 ) Certain significant items (b) — — 7,187 298 $ 12,680 $ 13,298 $ 10,727 $ 4,177 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 28,887 $ 27,737 $ 18,484 $ 17,987 Upjohn 8,077 9,302 5,577 6,442 Total reportable segments 36,964 37,040 24,062 24,428 Other business activities — — (3,750 ) (3,605 ) Reconciling Items: Corporate and other unallocated 2,098 2,631 (4,108 ) (4,558 ) Purchase accounting adjustments — — (3,357 ) (3,665 ) Acquisition-related costs — — (152 ) (221 ) Certain significant items (b) — — 6,495 452 $ 39,062 $ 39,670 $ 19,190 $ 12,831 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018 , and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million , (ii) charges for certain legal matters of $63 million , (iii) charges for business and legal entity alignment of $89 million , (iv) net gains recognized during the period on investments in equity securities of $3 million , (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B , Note 3 and Note 4. For Earnings in the third quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million , (ii) net charges for certain legal matters of $37 million , (iii) charges for business and legal entity alignment of $1 million , (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million , (ii) charges for certain legal matters of $72 million , (iii) certain asset impairment charges of $149 million , (iv) charges for business and legal entity alignment of $353 million , (v) net gains recognized during the period on investments in equity securities of $139 million , (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion , (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million , (ii) net credits for certain legal matters of $70 million , (iii) certain asset impairment charges of $31 million , (iv) charges for business and legal entity alignment of $5 million , (v) net gains recognized during the period on investments in equity securities of $460 million , (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4 .
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 10,108 $ 9,422 $ 6,503 $ 6,206 Upjohn 2,195 3,036 1,353 2,051 Total reportable segments 12,303 12,458 7,856 8,257 Other business activities — — (1,443 ) (1,298 ) Reconciling Items: Corporate and other unallocated 377 839 (1,431 ) (1,658 ) Purchase accounting adjustments — — (1,141 ) (1,309 ) Acquisition-related costs — — (300 ) (112 ) Certain significant items (b) — — 7,187 298 $ 12,680 $ 13,298 $ 10,727 $ 4,177 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 29, September 30, September 29, September 30, Reportable Segments: Biopharma $ 28,887 $ 27,737 $ 18,484 $ 17,987 Upjohn 8,077 9,302 5,577 6,442 Total reportable segments 36,964 37,040 24,062 24,428 Other business activities — — (3,750 ) (3,605 ) Reconciling Items: Corporate and other unallocated 2,098 2,631 (4,108 ) (4,558 ) Purchase accounting adjustments — — (3,357 ) (3,665 ) Acquisition-related costs — — (152 ) (221 ) Certain significant items (b) — — 6,495 452 $ 39,062 $ 39,670 $ 19,190 $ 12,831 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018 , and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million , (ii) charges for certain legal matters of $63 million , (iii) charges for business and legal entity alignment of $89 million , (iv) net gains recognized during the period on investments in equity securities of $3 million , (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B , Note 3 and Note 4. For Earnings in the third quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million , (ii) net charges for certain legal matters of $37 million , (iii) charges for business and legal entity alignment of $1 million , (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million , (ii) charges for certain legal matters of $72 million , (iii) certain asset impairment charges of $149 million , (iv) charges for business and legal entity alignment of $353 million , (v) net gains recognized during the period on investments in equity securities of $139 million , (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion , (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million , (ii) net credits for certain legal matters of $70 million , (iii) certain asset impairment charges of $31 million , (iv) charges for business and legal entity alignment of $5 million , (v) net gains recognized during the period on investments in equity securities of $460 million , (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4 .
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, % Change September 29, September 30, % Change U.S. $ 5,850 $ 6,361 (8 ) $ 18,360 $ 18,861 (3 ) Developed Europe (a) 2,135 2,231 (4 ) 6,450 6,657 (3 ) Developed Rest of World (b) 1,585 1,640 (3 ) 4,758 4,795 (1 ) Emerging Markets (c) 3,110 3,066 1 9,493 9,358 1 Revenues $ 12,680 $ 13,298 (5 ) $ 39,062 $ 39,670 (2 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the third quarter of 2019 and $1.8 billion in the third quarter of 2018 , and were $5.2 billion in the first nine months of 2019 and $5.3 billion in the first nine months of 2018 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS September 29, September 30, September 29, September 30, TOTAL REVENUES $ 12,680 $ 13,298 $ 39,062 $ 39,670 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a) $ 10,108 $ 9,422 $ 28,887 $ 27,737 Internal Medicine (b) $ 2,207 $ 2,182 $ 6,754 $ 6,529 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,025 870 3,121 2,524 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 276 261 825 789 Premarin family Symptoms of menopause 182 204 542 605 BMP2 Development of bone and cartilage 66 54 212 206 Toviaz Overactive bladder 61 67 186 197 All other Internal Medicine Various 597 727 1,867 2,208 Oncology (c) $ 2,350 $ 1,840 $ 6,547 $ 5,487 Ibrance Advanced breast cancer 1,283 1,025 3,677 2,985 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 224 248 704 785 Xtandi alliance revenues Castration-resistant prostate cancer 225 180 594 510 Xalkori ALK-positive and ROS1-positive advanced NSCLC 130 127 385 417 Inlyta Advanced RCC 139 71 316 226 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 90 69 267 206 Retacrit (j) Anemia 64 19 147 55 All other Oncology Various 194 101 456 302 Hospital (d) $ 1,917 $ 1,841 $ 5,717 $ 5,944 Sulperazon Treatment of infections 163 145 505 464 Medrol (e) Steroid anti-inflammatory 109 110 348 369 Vfend Fungal infections 87 87 265 294 Zithromax (e) Bacterial infections 77 61 254 243 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 92 68 238 215 Zyvox Bacterial infections 61 50 195 184 Fragmin Slows blood clotting 62 76 185 221 Zosyn/Tazocin Antibiotic 49 56 153 176 Tygacil Tetracycline class antibiotic 50 60 146 186 Pfizer CentreOne (f) Various 176 159 556 539 All other Anti-infectives Various 335 300 961 929 All other Hospital (d) Various 656 669 1,910 2,124 Vaccines $ 1,808 $ 1,845 $ 4,795 $ 4,708 Prevnar 13/Prevenar 13 Pneumococcal disease 1,603 1,660 4,268 4,290 FSME/IMMUN-TicoVac Tick-borne encephalitis disease 64 57 197 162 Nimenrix Meningococcal disease 52 46 159 95 Trumenba Meningococcal disease 73 61 117 95 All other Vaccines Various 16 21 54 65 Inflammation & Immunology (I&I) (g) $ 1,226 $ 1,184 $ 3,482 $ 3,419 Xeljanz RA, PsA, UC 599 432 1,634 1,221 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 415 531 1,285 1,589 Inflectra/Remsima (g), (j) Inflammatory diseases 155 166 446 469 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 43 40 92 104 All other I&I Various 15 14 24 36 (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS September 29, September 30, September 29, September 30, Rare Disease $ 601 $ 531 $ 1,592 $ 1,651 BeneFIX Hemophilia 125 132 372 420 Genotropin Replacement of human growth hormone 124 143 357 416 Refacto AF/Xyntha Hemophilia 104 117 319 388 Vyndaqel ATTR-Cardiomyopathy and Polyneuropathy 156 37 259 108 Somavert Acromegaly 64 64 192 195 All other Rare Disease Various 28 38 94 123 UPJOHN (b) , (h) $ 2,195 $ 3,036 $ 8,077 $ 9,302 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 527 1,213 2,888 3,649 Lipitor Reduction of LDL cholesterol 476 507 1,506 1,539 Norvasc Hypertension 219 248 735 777 Celebrex Arthritis pain and inflammation, acute pain 179 188 526 494 Viagra Erectile dysfunction 120 137 379 509 Effexor Depression and certain anxiety disorders 80 78 242 228 Zoloft Depression and certain anxiety disorders 74 72 217 223 Xalatan/Xalacom Glaucoma and ocular hypertension 68 76 201 233 Xanax Anxiety disorders 50 52 147 163 Revatio Pulmonary arterial hypertension 24 53 122 163 All other Upjohn Various 379 411 1,114 1,325 CONSUMER HEALTHCARE BUSINESS (i) $ 377 $ 839 $ 2,098 $ 2,631 Total Alliance revenues Various $ 1,141 $ 977 $ 3,418 $ 2,820 Total Biosimilars (j) Various $ 236 $ 197 $ 632 $ 558 Total Sterile Injectable Pharmaceuticals (k) $ 1,248 $ 1,239 $ 3,703 $ 3,928 (a) The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Disease. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) . (b) We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation. (c) We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation. (d) Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne (f) . All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (e) 2018 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category. (f) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation. (h) Pfizer’s Upjohn business encompasses primarily off-patent branded and generic medicines that includes a portfolio of 20 globally recognized solid oral dose brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone. (i) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 1A and Note 2B . (j) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (k) Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details) $ / shares in Units, $ in Millions		Jul. 30, 2019USD ($)$ / shares	Jul. 01, 2019USD ($)	Jan. 01, 2019USD ($)Accounting_standard	Sep. 29, 2019USD ($)	Sep. 29, 2019USD ($)Operating_Segment	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)Operating_Segment	Jul. 02, 2019USD ($)	Jun. 28, 2020	Jan. 01, 2018Accounting_standard
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments | Operating_Segment						3		2
Number of accounting standards adopted | Accounting_standard				4							11
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payment to acquire business, net of cash acquired	[1]					$ 10,861	$ 0
ROU assets					$ 1,306	1,306
Lease liabilities (long-term)					1,037	1,037
Accrued rebates and other accruals					5,557	5,557		$ 5,426
Variable lease payments					$ 74	$ 192
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROU assets				$ 1,400
Lease liabilities (long-term)				1,400
Cumulative effect adjustment to retained earnings, pre-tax				30
Cumulative effect adjustment to retained earnings, after-tax				$ 20
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease term					1 year	1 year
Operating lease term, option to extend						5 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease term					30 years	30 years
Operating lease term, option to extend						10 years
Array [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares		$ 48
Payments for acquisition, cash portion		$ 11,200
Payment to acquire business, net of cash acquired		$ 10,900
Upjohn And Mylan [Member] | Forecast [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Ownership percentage										57.00%
Upjohn And Mylan [Member] | Mylan [Member] | Forecast [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Ownership percentage by noncontrolling owners										43.00%
Therachon Asset Acquisition [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Upfront payment			$ 340
Maximum potential milestone payments			$ 470
Fair value of consideration transferred									$ 322
[1]	Amounts may not add due to rounding.

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details) - USD ($) $ in Millions	Sep. 29, 2019	[1]	Jan. 01, 2019	Dec. 31, 2018	[1]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other current assets	$ 2,954		$ 2,460	$ 2,461
Noncurrent deferred tax assets and other noncurrent tax assets	1,984		1,913	1,924
Other noncurrent assets	4,920		4,149	2,799
Other current liabilities	10,160		11,011	10,753
Other noncurrent liabilities	6,381		6,910	5,850
Retained earnings	$ 100,113		89,574	$ 89,554
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other current assets			(1)
Noncurrent deferred tax assets and other noncurrent tax assets			(11)
Other noncurrent assets			1,351
Other current liabilities			258
Other noncurrent liabilities			1,060
Retained earnings			$ 20
[1]	Amounts may not add due to rounding.

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 31, 2018
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 5,557	$ 5,426
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,203	1,288
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,275	3,208
Other accruals	617	531
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 463	$ 399

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details) $ in Millions	Sep. 29, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ROU assets	$ 1,306
Lease liabilities (short-term)	281
Lease liabilities (long-term)	$ 1,037

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies - Total Lease Costs (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2019	Sep. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating lease cost	$ 111	$ 310
Variable lease cost	74	192
Sublease income	(10)	(31)
Total lease cost	$ 174	$ 471

Basis of Presentation and Sig_9

Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating leases, weighted-average remaining contractual lease term	6 years 9 months 18 days
Operating lease, weighted-average discount rate	3.60%
Operating cash flows from operating leases	$ 244
(Gains)/losses on sale and leaseback transactions, net	(32)
ROU assets obtained in exchange for new operating lease liabilities	$ 250

Basis of Presentation and Si_10

Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 29, 2019	Apr. 30, 2018
Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]
Next one year	[1]				$ 322
1-2 years					279
2-3 years					222
3-4 years					176
4-5 years					110
Thereafter					406
Total undiscounted lease payments					1,516
Less: Imputed interest					197
Present Value of Minimum Lease Payments					1,319
Less: Current portion					281
Noncurrent portion					$ 1,037
Rental expense, net of sublease income		$ 301	$ 314	$ 292
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019		300
2020		252
2021		210
2022		267
2023		248
After 2023		$ 2,040
Office Building in New York City [Member]
Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]
Term of corporate headquarters lease agreement						20 years
Future minimum commitment for corporate headquarters lease						$ 1,700
[1]	Reflects lease payments due within 12 months subsequent to the balance sheet date.

Acquisitions, Equity-Method I_3

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Array BioPharma (Details) - USD ($) $ / shares in Units, $ in Millions		Jul. 30, 2019	Sep. 29, 2019	Sep. 29, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Acquisition of business, net of cash acquired	[1]			$ 10,861	$ 0
Goodwill	[2]		$ 58,665	58,665		$ 53,411
Array [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 48
Payments for acquisition, cash portion		$ 11,200
Acquisition of business, net of cash acquired		10,900
Identifiable intangible assets		7,200
Goodwill		5,400
Deferred tax liabilities		1,300
Assumed long-term debt		451
Array [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 1,800
Acquired intangible assets, average useful life		16 years
IPR&D [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 4,000
Licensing Agreements [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		1,400
Technology in development [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		1,100
Developed technology [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 340
Useful life of acquired intangibles		10 years
Restructuring charges and acquisition-related costs [Member] | Array [Member]
Business Acquisition [Line Items]
Post-closing compensation expense for payments to Array employees for fair value of previously unvested stock options			$ 157	$ 157
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Equity-Method I_4

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Therachon (Details) - Therachon Asset Acquisition [Member] - USD ($) $ in Millions	Jul. 01, 2019	Dec. 31, 2018	Jul. 02, 2019
Schedule of Asset Acquisition [Line Items]
Upfront payment	$ 340
Maximum potential milestone payments	470
Percentage of shares acquired		3.00%
Payment for asset acquisition	317	$ 5
Fair value of consideration transferred			$ 322
Charge to research and development expenses in connection with asset acquisition	$ 337

Acquisitions, Equity-Method I_5

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Equity Method Investments and Assets and Liabilities Held for Sale Narrative (Details) - USD ($) $ in Millions		Jul. 31, 2019	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Schedule of Equity Method Investments [Line Items]
(Gain) on completion of Consumer Healthcare JV transaction	[1]		$ (8,087)	$ 0	$ (8,087)	$ 0
GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		32.00%
(Gain) on completion of Consumer Healthcare JV transaction			(8,100)
Gain on joint venture formation, net of tax			$ 5,400
Tax indemnification liability		$ 45
Fair value of equity method investment		$ 15,700
Term of administrative services in accordance with transitional agreements		24 years
Term of manufacture and supply agreements in accordance with transitional agreement		6 years
GSK [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		68.00%
[1]	Amounts may not add due to rounding.

Acquisitions, Equity-Method I_6

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total Consumer Healthcare liabilities held for sale	[1]	$ 0		$ 0		$ 1,890
Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other assets held for sale	[2]					46
Assets held for sale						9,725
Consumer Healthcare [Member] | Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents						32
Trade accounts receivable, less allowance for doubtful accounts						532
Inventories						538
Other current assets						56
PP&E						675
Identifiable intangible assets, less accumulated amortization						5,763
Goodwill						1,972
Noncurrent deferred tax assets and other noncurrent tax assets						54
Other noncurrent assets						57
Assets held for sale						9,678
Trade accounts payable						406
Income taxes payable						39
Accrued compensation and related items						93
Other current liabilities						353
Pension benefit obligations, net						39
Postretirement benefit obligations, net						33
Noncurrent deferred tax liabilities						870
Other noncurrent liabilities						56
Total Consumer Healthcare liabilities held for sale						$ 1,890
Pre-tax income on a management business unit basis		$ 100	$ 211	$ 654	$ 725
[1]	Amounts may not add due to rounding.
[2]	Other assets held for sale consist of PP&E.

Acquisitions, Equity-Method I_7

Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Research and Development Arrangement (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
		Apr. 30, 2016	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	[1],[2]		$ 2,283,000,000	$ 2,008,000,000	$ 5,827,000,000	$ 5,549,000,000
NovaQuest Co-Investment Fund V, L.P. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development arrangement, maximum funding amount		$ 200,000,000
Research and development arrangement, percentage of costs to be reimbursed		100.00%
Research and development arrangement, maximum funding amount, term		3 years 3 months
Research and development arrangement, contingent payments, maximum exposure		$ 267,000,000
Research and development arrangement, contingent payments, term		8 years
Charge in cost of sales for inventory build for eventual commercial use/expected future sale			127,000,000
Research and development expenses			$ 15,000,000
[1]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[2]	Amounts may not add due to rounding.

Restructuring Charges and Oth_3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 29, 2019USD ($)Operating_Segment	Dec. 31, 2018Operating_Segment
Restructuring Cost and Reserve [Line Items]
Number of business segments | Operating_Segment	3	2
Restructuring costs incurred	$ 452
2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 600
Percentage of expected costs to be non-cash	15.00%
Restructuring costs incurred	$ 300
Manufacturing Optimization [Member] | 2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	819
Other Activities [Member] | 2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	945
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	(194)
Array [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	272
Hospira [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	$ 74

Restructuring Charges and Oth_4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019		Sep. 30, 2018
Restructuring charges:
Employee terminations		$ 82	$ (24)	$ (86)		$ (53)
Asset impairments		3	12	3		8
Exit costs/(credits)		(1)	14	33		14
Restructuring charges/(credits)	[1]	83	1	(50)	[2]	(32)
Transaction costs	[3]	65	1	65		1
Integration costs and other	[4]	217	82	281		202
Restructuring charges and certain acquisition-related costs	[5]	365	85	295		172
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[6]	6	12	29		43
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[7]	40	48	109		130
Total costs associated with acquisitions and cost-reduction/productivity initiatives		420	186	452		447
Other (income)/deductions––net [Member]
Restructuring charges:
Net periodic benefit costs recorded in Other (income)/deductions––net		9	41	19		103
Cost of sales [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[6]	6	12	21		43
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[7]	14	21	45		57
Selling, informational and administrative expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[6]	0	0	2		0
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[7]	23	17	48		51
Research and development expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[6]	0	0	6		0
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[7]	$ 3	$ 9	$ 16		$ 22
[1]	In the third quarter of 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives as well as our acquisition of Array. In the first nine months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Note 5B ), partially offset by employee termination costs associated with cost-reduction and productivity initiatives, as well as our acquisition of Array. In the third quarter of 2018, restructuring charges were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs. In the first nine months of 2018, restructuring credits were mostly related to the reversal of previously recorded accruals for employee termination costs. The restructuring activities for 2019 are associated with the following: • For the third quarter of 2019 , Biopharma ( $10 million charge ); Upjohn ( $6 million credit ); and Other ( $79 million charge). • For the first nine months of 2019 , Biopharma ( $38 million credit); Upjohn ( $27 million credit ); and Other ( $15 million charge). The restructuring activities for 2018 are associated with the following: • For the third quarter of 2018, total reportable segments ( $6 million credit); and Other ( $7 million charge). • For the first nine months of 2018, total reportable segments ( $30 million credit); and Other ( $2 million credit). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[2]	Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Note 5B for additional information.
[3]	Transaction costs represent external costs for banking, legal, accounting and other similar services. In the third quarter and first nine months of 2019, transaction costs relate to our acquisition of Array.
[4]	Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the third quarter and first nine months of 2019, integration costs and other primarily includes $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see Note 2A ). In the third quarter and first nine months of 2018, integration costs and other were primarily related to our acquisition of Hospira.
[5]	Amounts may not add due to rounding.
[6]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[7]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth_5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019		Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)	[1]	$ 83	$ 1	$ (50)	[2]	$ (32)
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		79	7	15		(2)
Biopharma and Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)			$ (6)			$ (30)
Biopharma [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		10		(38)
Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		(6)		(27)
Restructuring charges and acquisition-related costs [Member] | Array [Member]
Restructuring Cost and Reserve [Line Items]
Post-closing compensation expense for payments to Array employees for fair value of previously unvested stock options		$ 157		$ 157
[1]	In the third quarter of 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives as well as our acquisition of Array. In the first nine months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Note 5B ), partially offset by employee termination costs associated with cost-reduction and productivity initiatives, as well as our acquisition of Array. In the third quarter of 2018, restructuring charges were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs. In the first nine months of 2018, restructuring credits were mostly related to the reversal of previously recorded accruals for employee termination costs. The restructuring activities for 2019 are associated with the following: • For the third quarter of 2019 , Biopharma ( $10 million charge ); Upjohn ( $6 million credit ); and Other ( $79 million charge). • For the first nine months of 2019 , Biopharma ( $38 million credit); Upjohn ( $27 million credit ); and Other ( $15 million charge). The restructuring activities for 2018 are associated with the following: • For the third quarter of 2018, total reportable segments ( $6 million credit); and Other ( $7 million charge). • For the first nine months of 2018, total reportable segments ( $30 million credit); and Other ( $2 million credit). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[2]	Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Note 5B for additional information.

Restructuring Charges and Oth_6

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019		Sep. 30, 2018
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]			$ 1,252
Provision/(credit)	[2]	$ 83	$ 1	(50)	[3]	$ (32)
Utilization and other	[4]			(467)
Balance, September 29, 2019	[5]	734		734
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]			1,203
Provision/(credit)	[3]			(86)
Utilization and other	[4]			(431)
Balance, September 29, 2019	[5]	686		686
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]			0
Provision/(credit)	[3]			3
Utilization and other	[4]			(3)
Balance, September 29, 2019	[5]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]			49
Provision/(credit)	[3]			33
Utilization and other	[4]			(33)
Balance, September 29, 2019	[5]	$ 48		$ 48
[1]	Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ).
[2]	In the third quarter of 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives as well as our acquisition of Array. In the first nine months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Note 5B ), partially offset by employee termination costs associated with cost-reduction and productivity initiatives, as well as our acquisition of Array. In the third quarter of 2018, restructuring charges were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs. In the first nine months of 2018, restructuring credits were mostly related to the reversal of previously recorded accruals for employee termination costs. The restructuring activities for 2019 are associated with the following: • For the third quarter of 2019 , Biopharma ( $10 million charge ); Upjohn ( $6 million credit ); and Other ( $79 million charge). • For the first nine months of 2019 , Biopharma ( $38 million credit); Upjohn ( $27 million credit ); and Other ( $15 million charge). The restructuring activities for 2018 are associated with the following: • For the third quarter of 2018, total reportable segments ( $6 million credit); and Other ( $7 million charge). • For the first nine months of 2018, total reportable segments ( $30 million credit); and Other ( $2 million credit). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[3]	Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Note 5B for additional information.
[4]	Includes adjustments for foreign currency translation.
[5]	Included in Other current liabilities ( $535 million ) and Other noncurrent liabilities ( $199 million ).

Restructuring Charges and Oth_7

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Sep. 29, 2019		Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 734	[1]	$ 1,252	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	535		823
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 199		$ 428
[1]	Included in Other current liabilities ( $535 million ) and Other noncurrent liabilities ( $199 million ).
[2]	Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ).

Other (Income)_Deductions - N_3

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Other Income and Expenses [Abstract]
Interest income	[1]	$ (60)	$ (82)	$ (185)	$ (240)
Interest expense	[1]	409	310	1,158	946
Net interest expense		348	228	973	706
Royalty-related income	[2]	(155)	(143)	(475)	(360)
Net gains on asset disposals		(32)	(4)	(33)	(19)
Net gains recognized during the period on investments in equity securities	[3],[4]	(6)	(85)	(153)	(460)
Net realized losses on sales of investments in debt securities		0	8	0	19
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[5]	(20)	(139)	(124)	(455)
Net periodic benefit credits other than service costs	[6]	(19)	(65)	(110)	(231)
Certain legal matters, net	[7]	64	37	84	(70)
Certain asset impairments	[8]	28	(1)	188	40
Business and legal entity alignment costs	[9]	87	1	343	5
Net losses on early retirement of debt	[10]	0	0	138	3
Other, net	[11]	24	(252)	(294)	(322)
Other (income)/deductions––net	[12]	$ 319	$ (414)	$ 537	$ (1,143)
[1]	Interest income decreased in the third quarter and first nine months of 2019 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2019 , mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year periods.
[2]	The increase in royalty-related income for the first nine months of 2019 is primarily due to a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million .
[3]	The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B .
[4]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[5]	Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first nine months of 2019 , mainly includes, among other things, $70 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® (fluticasone propionate and salmeterol inhalation powder) and $26 million in milestone income from multiple licensees. In the third quarter of 2018 , primarily included, among other things, (i) $40 million in milestone income from a certain licensee, (ii) a $35 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of Crohn’s disease and (iii) $45 million in gains related to sales of compound/product rights. In the first nine months of 2018 , mainly included, among other things, (i) approximately $128 million in milestone income from multiple licensees, (ii) an upfront payment to us of $75 million for the sale of an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator for cognitive impairment associated with schizophrenia (CIAS) to Biogen Inc., (iii) $110 million in milestone payments received from Shire, of which $75 million was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis and $35 million was received from Shire related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn’s disease, (iv) a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU and (v) $45 million in gains related to sales of compound/product rights.
[6]	For additional information, see Note 10 .
[7]	For the first nine months of 2018 , the net credits primarily represented the reversal of a legal accrual where a loss was no longer deemed probable.
[8]	The first nine months of 2019 include an intangible asset impairment charge of $10 million and the first nine months of 2018 included an intangible asset impairment charge of $31 million recorded in the second quarter of 2018, which are all related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflect , among other things, updated commercial forecasts. The first nine months of 2019 also includes intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first nine months of 2019 , includes other asset impairments of $48 million .
[9]	In the third quarter and first nine months of 2019, and in the third quarter of 2018, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first nine months of 2018, mainly represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[10]	In the first nine months of 2019 , represents net losses due to the early retirement of debt in the first quarter of 2019, inclusive of the related termination of cross-currency swaps.
[11]	The third quarter of 2019 includes, among other things, dividend income of $43 million from our investment in ViiV and charges of $121 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. The first nine months of 2019 includes, among other things, (i) dividend income of $184 million from our investment in ViiV, (ii) charges of $146 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) $50 million of income from insurance recoveries related to Hurricane Maria. The third quarter and first nine months of 2018 included a non-cash $343 million pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. The third quarter of 2018 also included, among other things, dividend income of $91 million from our investment in ViiV, and charges of $122 million , reflecting the change in the fair value of contingent consideration. The first nine months of 2018 also included, among other things, (i) dividend income of $226 million from our investment in ViiV, (ii) charges of $257 million , reflecting the change in the fair value of contingent consideration, (iii) a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T development program assets obtained from Cellectis S.A. and Les Laboratoires Servier SAS in connection with our contribution agreement entered into with Allogene, and (iv) a non-cash $17 million gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg.
[12]	Amounts may not add due to rounding.

Other (Income)_Deductions - N_4

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended					9 Months Ended
		Sep. 29, 2019	Jun. 30, 2019	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Sep. 29, 2019	Sep. 30, 2018
Loss Contingencies [Line Items]
Proceeds from favorable resolution of legal dispute			$ 82
Gains related to equity securities	[1],[2]	$ 6		$ 85			$ 153	$ 460
Intangible asset impairment charge					$ 31		10
Other asset impairments							48
External incremental costs		146					121
Income from insurance recoveries							50
Change in fair value of contingent consideration				122				257
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income		$ 43		91			184	226
Allogene [Member]
Loss Contingencies [Line Items]
Non-cash pre-tax gain on contribution of assets								50
Mylan [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received							70
Shire [Member] | Licensing Agreements [Member]
Loss Contingencies [Line Items]
Proceeds from licensing arrangement				35		$ 75		110
Merck [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received								40
Bain Capital [Member] | Cerevel [Member]
Loss Contingencies [Line Items]
Gains related to equity securities				343				343
Disposed of by Sale [Member] | HIS [Member]
Loss Contingencies [Line Items]
Gains related to equity securities				24				229
Disposed of by Sale [Member] | AMPA Receptor Potentiator For CIAS [Member]
Loss Contingencies [Line Items]
Consideration transferred				75				75
Distribution Rights [Member]
Loss Contingencies [Line Items]
Gain related to sales of compound/product rights				45				45
Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[3]						50
In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[3]						90
WRDM [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge							90
Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge							40
Other (income)/deductions––net [Member] | Licensing Agreements [Member]
Loss Contingencies [Line Items]
Milestone payment received				$ 40			$ 26	128
Mylotarg [Member] | EU [Member] | Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Non-cash gain on cash settlement of liability								$ 17
[1]	The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B .
[2]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[3]	Reflects intangible assets written down to fair value in the first nine months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other (Income)_Deductions - N_5

Other (Income)/Deductions - Net - Intangible Assets (Details) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
		Jul. 01, 2018	Sep. 29, 2019
Finite-Lived Intangible Assets [Line Items]
Total	[1]		$ 13
Impairment		$ 31	10
Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	[1],[2]		13
Impairment	[2]		50
Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	[1]		0
Level 1 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	[1],[2]		0
Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	[1]		0
Level 2 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	[1],[2]		0
Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	[1]		13
Level 3 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	[1],[2]		13
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	[1],[2]		0
Impairment	[2]		90
In Process Research and Development [Member] | Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	[1],[2]		0
In Process Research and Development [Member] | Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	[1],[2]		0
In Process Research and Development [Member] | Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	[1],[2]		$ 0
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.
[2]	Reflects intangible assets written down to fair value in the first nine months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			9 Months Ended
	Apr. 30, 2019	Sep. 29, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Taxes [Line Items]
Benefit recorded as a result of tax settlement			$ 1,400
Effective tax rate for income from continuing operations		28.40%		1.60%	13.40%	9.90%
Tax expense associated with gain related to completion of Consumer Healthcare joint venture transaction					$ 2,700
Repatriation tax liability		$ 15,000			15,000
First installment for repatriation tax	$ 750
Income Taxes Payable [Member]
Income Taxes [Line Items]
Repatriation tax liability		$ 750			$ 750

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency translation adjustments, net	[1]	$ 86	$ 14	$ 96	$ 82
Unrealized holding gains on derivative financial instruments, net		31	35	37	39
Reclassification adjustments for (gains)/losses included in net income		(3)	(28)	(62)	36
Derivatives qualifying as hedges, tax, total		28	7	(24)	77
Unrealized holding gains/(losses) on available-for-sale securities, net		2	20	6	(8)
Reclassification adjustments for (gains)/losses included in net income		(1)	(6)	4	(8)
Available-for-sale securities, tax, total		1	14	10	(62)
Benefit plans: actuarial gains/(losses), net		(41)	2	(42)	27
Reclassification adjustments related to amortization		23	15	41	43
Reclassification adjustments related to settlements, net		9	10	10	25
Other		(1)	11	2	18
Defined benefit plans, actuarial gain (loss), tax, total		(10)	38	12	750
Benefit plans: prior service costs and other, net		0	0	0	0
Reclassification adjustments related to amortization of prior service costs and other, net		(11)	(11)	(33)	(33)
Reclassification adjustments related to curtailments of prior service costs and other, net		(11)	(1)	(11)	(4)
Other		1	1	1	1
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(21)	(11)	(43)	(179)
Tax provision on other comprehensive loss	[2]	84	62	50	667
ASU 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	0	0	1
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	0	0	637
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	0	0	(144)
ASU 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings	[4]	$ 0	$ 0	$ 0	$ (45)
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
[4]	For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements–– Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	$ 63,407	[1]
Balance, September 29, 2019	65,103	[1]
Foreign currency translation adjustments loss attributable to noncontrolling interests	11
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(11,275)
Other comprehensive income/(loss)	(525)	[2]
Balance, September 29, 2019	(11,801)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(6,075)
Other comprehensive income/(loss)	(443)	[2]
Balance, September 29, 2019	(6,519)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	167
Other comprehensive income/(loss)	(107)	[2]
Balance, September 29, 2019	60
Cash flow hedge gain to be reclassified within twelve months	247
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(68)
Other comprehensive income/(loss)	68	[2]
Balance, September 29, 2019	0
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(6,027)
Other comprehensive income/(loss)	94	[2]
Balance, September 29, 2019	(5,933)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	728
Other comprehensive income/(loss)	(137)	[2]
Balance, September 29, 2019	$ 591
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first nine months of 2019 .

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[1]	$ 1,054	$ 1,600
Total assets	[2]	170,446	159,422
Total liabilities		733	1,024
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		8,803	19,595
Total liabilities		733	1,024
Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		1,054	1,600
Available-for-sale debt securities		4,270	15,091
Total short-term investments		5,324	16,691
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		618	574
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		59	97
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		559	477
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	1,530	1,273
Available-for-sale debt securities		408	491
Total long-term investments		1,937	1,764
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		924	566
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		557	335
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		367	232
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		133	82
Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	5
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		133	78
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	942
Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	378
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	564
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,513	1,260
Total liabilities		0	0
Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		7	17
Available-for-sale debt securities		0	0
Total short-term investments		7	17
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	1,506	1,243
Available-for-sale debt securities		0	0
Total long-term investments		1,506	1,243
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		7,290	18,335
Total liabilities		733	1,024
Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		1,047	1,583
Available-for-sale debt securities		4,270	15,091
Total short-term investments		5,317	16,674
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		618	574
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		59	97
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		559	477
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	24	30
Available-for-sale debt securities		408	491
Total long-term investments		432	521
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		924	566
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		557	335
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		367	232
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		133	82
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	5
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		133	78
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	942
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	378
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	564
Money market funds [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		1,035	1,571
Money market funds [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		0	0
Money market funds [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		1,035	1,571
Equity [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	19	29
Equity [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	7	17
Equity [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	12	11
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,543	9,703
Government and agency - non U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,498	9,609
Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		45	94
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,498	9,609
Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		45	94
Corporate and other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[4]	2,135	5,878
Corporate and other [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,772	5,482
Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		363	397
Corporate and other [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,772	5,482
Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 363	$ 397
[1]	As of September 29, 2019 and December 31, 2018 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[2]	Amounts may not add due to rounding.
[3]	As of September 29, 2019 , short-term equity securities of $12 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[4]	Primarily issued by a diverse group of corporations.

Financial Instruments - Finan_2

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - Recurring [Member] - USD ($) $ in Millions	Sep. 29, 2019	Dec. 31, 2018
Footnotes to selected financial assets and liabilities:
Short-term equity securities held in trust	$ 12	$ 11
Long-term equity securities held in trust	$ 23	$ 29

Financial Instruments - Finan_3

Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 31, 2018
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 36,044	$ 32,909
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	40,873	35,260
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 40,873	$ 35,260

Financial Instruments - Total S

Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Short-term investments
Equity securities with readily determinable fair value	[1]	$ 1,054	$ 1,600
Available-for-sale debt securities		4,270	15,091
Held-to-maturity debt securities		978	1,003
Total Short-term investments	[2]	6,302	17,694
Long-term investments
Equity securities with readily determinable fair values		1,530	1,273
Available-for-sale debt securities		408	491
Held-to-maturity debt securities		43	59
Private equity investments at cost		742	763
Total Long-term investments	[2]	2,723	2,586
Equity-method investments	[2]	15,999	181
Total long-term investments and equity-method investments		18,721	2,767
Held-to-maturity cash equivalents		$ 217	$ 199
[1]	As of September 29, 2019 and December 31, 2018 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[2]	Amounts may not add due to rounding.

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost		$ 5,916	$ 16,920
Debt securities, gross unrealized gains		11	8
Debt securities, gross unrealized losses		(12)	(85)
Available-for-sale securities and held-to-maturity securities		5,915	16,842
Debt securities maturities, within 1 year, fair value		5,464
Debt securities maturities, over 1 to 5 years, fair value		413
Debt securities maturities, over 5 years, fair value		38
Government and agency - non U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		2,538	9,754
Available-for-sale debt securities, gross unrealized gains		11	7
Available-for-sale debt securities, gross unrealized losses		(6)	(58)
Available-for-sale debt securities, fair value		2,543	9,703
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		2,498
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		45
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		2,543	9,703
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		601	592
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		601	592
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		601
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		0
Held-to-maturity securities, debt maturities, total		601	592
Corporate and other [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	[1]	2,140	5,905
Available-for-sale debt securities, gross unrealized gains	[1]	1	0
Available-for-sale debt securities, gross unrealized losses	[1]	(6)	(27)
Available-for-sale debt securities, fair value	[1]	2,135	5,878
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[1]	1,772
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[1]	360
Available-for-sale securities, debt maturities, over 5 years, fair value	[1]	2
Available-for-sale debt securities, fair value	[1]	2,135	5,878
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		636	668
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		636	668
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		593
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		8
Held-to-maturity securities, debt maturities, over 5 years, fair value		35
Held-to-maturity securities, debt maturities, total		$ 636	$ 668
[1]	Primarily issued by a diverse group of corporations.

Financial Instruments - Inves_2

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Financial Instruments [Abstract]
Net gains recognized during the period on investments in equity securities	[1],[2]	$ (6)	$ (85)	$ (153)	$ (460)
Less: Net gains recognized during the period on equity securities sold during the period		(3)	(58)	(13)	(105)
Net unrealized gains during the reporting period on equity securities still held at the reporting date		$ (3)	$ (27)	$ (140)	$ (355)
[1]	The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B .
[2]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Financial Instruments [Abstract]
Commercial paper		$ 12,914	$ 3,100
Current portion of long-term debt, principal amount		2,423	4,781
Other short-term borrowings, principal amount	[1]	1,334	966
Total short-term borrowings, principal amount		16,671	8,847
Net fair value adjustments related to hedging and purchase accounting		7	(5)
Net unamortized discounts, premiums and debt issuance costs		(61)	(11)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[2]	$ 16,617	$ 8,831
[1]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E .
[2]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt - New Issuances (Details) - Senior Notes [Member] - USD ($) $ in Millions		Sep. 29, 2019	Jun. 03, 2016
Debt Instrument [Line Items]
Principal	[1]	$ 5,000
Weighted-average effective interest rate			3.57%
2.800% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 500
Stated interest rate		2.80%
2.950% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 750
Stated interest rate		2.95%
3.450% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 1,750
Stated interest rate		3.45%
3.900% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 750
Stated interest rate		3.90%
4.000% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 1,250
Stated interest rate		4.00%
[1]	The weighted-average effective interest rate for the notes at issuance was 3.57% .
[2]	Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.

Financial Instruments - Long-_2

Financial Instruments - Long-Term Debt Narrative (Details) $ in Millions, € in Billions		1 Months Ended	3 Months Ended		9 Months Ended
		Jan. 31, 2019USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Jan. 31, 2019EUR (€)
Debt Instrument [Line Items]
Loss on extinguishment of debt	[1]		$ 0	$ 0	$ 138	$ 3
5.75% notes [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 138
Senior Notes [Member] | 5.75% notes [Member]
Debt Instrument [Line Items]
Repurchase amount		$ 1,300					€ 1.1
Stated interest rate		5.75%					5.75%
Redemption value		$ 1,500					€ 1.3
[1]	In the first nine months of 2019 , represents net losses due to the early retirement of debt in the first quarter of 2019, inclusive of the related termination of cross-currency swaps.

Financial Instruments - Long-_3

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting		$ 7	$ (5)
Net unamortized discounts, premiums and debt issuance costs		(61)	(11)
Total long-term debt, carried at historical proceeds, as adjusted	[1]	36,044	32,909
Current portion of long-term debt, carried at historical proceeds, as adjusted	[1]	2,431	4,776
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount		34,602	32,558
Net fair value adjustments related to hedging and purchase accounting		1,614	479
Net unamortized discounts, premiums and debt issuance costs		(179)	(136)
Other long-term debt		7	7
Total long-term debt, carried at historical proceeds, as adjusted		36,044	32,909
Current portion of long-term debt, carried at historical proceeds, as adjusted		$ 2,431	$ 4,776
[1]	Amounts may not add due to rounding.

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Derivative [Line Items]
Asset		$ 1,542	$ 1,140
Liability		733	1,024
Derivatives designated as hedging instruments [Member]
Derivative [Line Items]
Asset		1,425	1,085
Liability		621	968
Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	22,807	22,984
Asset	[1]	810	654
Liability	[1]	621	586
Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		6,645	11,145
Asset		616	432
Liability		0	383
Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		18,112	15,154
Asset		116	55
Liability		112	55
Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 6,600	$ 5,800
[1]	The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.6 billion as of September 29, 2019 and $5.8 billion as of December 31, 2018.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1]	$ 150	$ 222	$ 241	$ 236
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	(1)	0	0	1
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	429	304	617	629
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[4]	29	235	372	(119)
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	(77)	150	(201)	156
Other (Income) Deductions And Cost Of Sales [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	0	0	0	1
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	74	256	472	(72)
Derivative Financial Instruments in Hedge Relationships [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[5]	131	183	137	147
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	112	43	87	191
Derivative Financial Instruments in Hedge Relationships [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[6]	45	8	65	50
Derivative Financial Instruments in Hedge Relationships [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[6]	79	17	89	111
Derivative Financial Instruments in Hedge Relationships [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	0	1	0	5
Hedged item	[3]	0	(1)	0	(5)
Derivative Financial Instruments in Hedge Relationships [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	378	(195)	1,191	(715)
Hedged item	[3]	(378)	195	(1,191)	715
Derivative Financial Instruments in Hedge Relationships [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[5]	7	198	265	(204)
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	0	0	0	0
Derivative Financial Instruments in Hedge Relationships [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[6]	0	0	0	0
Derivative Financial Instruments in Hedge Relationships [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[6]	0	0	0	0
Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	(77)	150	(201)	156
Cash Flow Hedging [Member] | Derivative Financial Instruments in Hedge Relationships [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3]	21	39	105	87
Cash Flow Hedging [Member] | Derivative Financial Instruments in Hedge Relationships [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3]	22	36	108	84
Net Investment Hedging [Member] | Derivative Financial Instruments in Hedge Relationships [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3]	43	14	136	41
Net Investment Hedging [Member] | Derivative Financial Instruments in Hedge Relationships [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3]	$ 45	$ 21	$ 99	$ 47
[1]	Amounts may not add due to rounding.
[2]	For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income–– Unrealized holding gains on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net.
[3]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income .
[4]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[5]	Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $252 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
[6]	Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of September 29, 2019 , which are used as hedging instruments in net investment hedges. The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 29, September 30, September 29 September 30, Cost of sales $ 2,602 $ 2,694 $ 7,611 $ 8,173 Other (income)/deductions—net 319 (414 ) 537 (1,143 )

Financial Instruments - Deriv_2

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Derivative [Line Items]
Pre-tax gain expected to be reclassified within the next 12 months		$ 252
Short-term debt	[1]	16,617	$ 8,831
Unsecured Debt [Member]
Derivative [Line Items]
Long-term debt		1,800
Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Short-term debt		1,100
Foreign currency long-term debt [Member]
Derivative [Line Items]
Long-term debt		$ 1,900
[1]	Amounts may not add due to rounding.

Financial Instruments - Fair _2

Financial Instruments - Fair Value And Cash Flow Hedges (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Financial Instruments [Abstract]
Cost of sales	[1],[2]	$ 2,602	$ 2,694	$ 7,611	$ 8,173
Other (income)/deductions––net	[2]	$ 319	$ (414)	$ 537	$ (1,143)
[1]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[2]	Amounts may not add due to rounding.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Long-term investments [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Assets	[1]	$ 45	$ 45
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset		0	(1)
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset		0	0
Short-term borrowings, including current portion of long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	0	1,499
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		0	(5)
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		0	0
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	7,101	9,952
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		557	(45)
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		$ 700	$ 129
[1]	Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) $ in Millions	Sep. 29, 2019USD ($)
Financial Instruments [Abstract]
Derivatives in a net liability position	$ (673)
Collateral posted	661
Cash collateral received	$ 1,300

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Billions	9 Months Ended
	Sep. 29, 2019USD ($)
Bank sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 2.7

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished goods		$ 2,594	$ 2,262
Work-in-process		4,866	4,701
Raw materials and supplies		762	546
Inventories	[1],[2]	8,222	7,508
Noncurrent inventories not included above	[3]	$ 677	$ 618
[1]	The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C ).
[2]	Amounts may not add due to rounding.
[3]	Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_3

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 9,023	$ 4,165
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		93,910	91,788
Finite-lived intangible assets, accumulated amortization	[1],[2]	(63,938)	(60,743)
Finite-lived intangible assets, net		29,972	31,045
Intangible assets, gross carrying amount	[1],[2]	102,933	95,954
Finite-lived intangible assets, accumulated amortization	[1],[2]	(63,938)	(60,743)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2],[3]	38,995	35,211
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		1,991	1,991
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[2]	5,959	2,171
License Agreements and Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[2],[4]	1,073	3
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[2]	91,212	89,430
Finite-lived intangible assets, accumulated amortization	[2]	(62,032)	(58,895)
Finite-lived intangible assets, net	[2]	29,180	30,535
Finite-lived intangible assets, accumulated amortization	[2]	(62,032)	(58,895)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		922	923
Finite-lived intangible assets, accumulated amortization		(733)	(708)
Finite-lived intangible assets, net		190	215
Finite-lived intangible assets, accumulated amortization		(733)	(708)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[2]	1,776	1,436
Finite-lived intangible assets, accumulated amortization	[2]	(1,173)	(1,140)
Finite-lived intangible assets, net	[2]	603	296
Finite-lived intangible assets, accumulated amortization	[2]	$ (1,173)	$ (1,140)
[1]	The increase in I dentifiable intangible assets, less accumulated amortization , is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments.
[2]	The increase in the gross carrying amount of I dentifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreement s (see Note 2A ).
[3]	Amounts may not add due to rounding.
[4]	Reflects acquired licensing agreements for technology in development.

Identifiable Intangible Asset_4

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - Array [Member] $ in Millions	Jul. 30, 2019USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets	$ 7,200
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets	1,800
Developed technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets	340
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets	4,000
Technology in development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets	$ 1,100

Identifiable Intangible Asset_5

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Sep. 29, 2019
Operating Segments [Member] | Developed Technology Rights [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	99.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
Operating Segments [Member] | Brands [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Operating Segments [Member] | Brands [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	98.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	2.00%

Identifiable Intangible Asset_6

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Sep. 29, 2019
Biopharma [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	42.00%
Biopharma [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	95.00%
Biopharma [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Upjohn [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	58.00%
Upjohn [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Upjohn [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	5.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset_7

Identifiable Intangible Assets and Goodwill - Narrative (Detail) $ in Billions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)Operating_Segment	Sep. 30, 2018USD ($)	Dec. 31, 2018Operating_Segment
Finite-Lived Intangible Assets [Line Items]
Number of segments | Operating_Segment			3		2
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets | $	$ 1.2	$ 1.3	$ 3.6	$ 3.7

Identifiable Intangible Asset_8

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2018	$ 53,411	[1]
Additions	5,378	[2]
Other	(123)	[3]
Balance, September 29, 2019	58,665	[1]
Biopharma [Member]
Goodwill [Roll Forward]
Additions	5,378	[2]
Upjohn [Member]
Goodwill [Roll Forward]
Additions	0	[2]
Operating Segments [Member] | Biopharma [Member]
Goodwill [Roll Forward]
Balance, December 31, 2018	42,927
Other	(99)	[3]
Balance, September 29, 2019	48,206
Operating Segments [Member] | Upjohn [Member]
Goodwill [Roll Forward]
Balance, December 31, 2018	10,484
Other	(24)	[3]
Balance, September 29, 2019	$ 10,460
[1]	Amounts may not add due to rounding.
[2]	Biopharma additions relate to our acquisition of Array (see Note 2A ).
[3]	Primarily reflects the impact of foreign exchange.

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	157	149	472	450
Expected return on plan assets	(222)	(259)	(667)	(783)
Amortization of:
Actuarial losses	37	30	110	90
Prior service costs/(credits)	(1)	0	(2)	1
Curtailments	0	1	0	11
Settlements	1	38	3	84
Special termination benefits	3	0	4	0
Defined benefit plan, net periodic benefit cost	(25)	(40)	(80)	(147)
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	31	33	94	104
Interest cost	53	52	162	160
Expected return on plan assets	(79)	(89)	(239)	(274)
Amortization of:
Actuarial losses	20	25	61	77
Prior service costs/(credits)	(1)	(1)	(3)	(3)
Curtailments	0	(4)	0	(4)
Settlements	12	0	12	0
Special termination benefits	0	0	0	1
Defined benefit plan, net periodic benefit cost	37	17	88	61
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost	12	14	37	40
Expected return on plan assets	0	0	0	0
Amortization of:
Actuarial losses	2	3	7	10
Prior service costs/(credits)	0	0	(1)	(1)
Curtailments	0	1	0	1
Settlements	22	3	21	24
Special termination benefits	5	0	14	0
Defined benefit plan, net periodic benefit cost	41	20	78	75
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	9	10	28	29
Interest cost	19	18	57	54
Expected return on plan assets	(8)	(9)	(25)	(28)
Amortization of:
Actuarial losses	0	2	2	5
Prior service costs/(credits)	(43)	(45)	(132)	(135)
Curtailments	(47)	(1)	(47)	(15)
Settlements	(10)	0	(10)	0
Special termination benefits	1	0	2	0
Defined benefit plan, net periodic benefit cost	$ (78)	$ (26)	$ (124)	$ (89)

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans (Detail) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended September 29, 2019	$ 8
Expected contributions from our general assets during 2019	11	[1]
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended September 29, 2019	158
Expected contributions from our general assets during 2019	191	[1]
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended September 29, 2019	122
Expected contributions from our general assets during 2019	147	[1]
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended September 29, 2019	103
Expected contributions from our general assets during 2019	$ 143	[1]
[1]	Contributions expected to be made for 2019 are inclusive of amounts contributed during the nine months ended September 29, 2019 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att_3

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
EPS Numerator––Basic
Income from continuing operations	[1]	$ 7,680	$ 4,111	$ 16,625	$ 11,562
Less: Net income attributable to noncontrolling interests		4	8	19	25
Income from continuing operations attributable to Pfizer Inc.		7,676	4,103	16,606	11,537
Less: Preferred stock dividends––net of tax		0	0	1	1
Income from continuing operations attributable to Pfizer Inc. common shareholders		7,676	4,103	16,605	11,536
Discontinued operations––net of tax	[1]	4	11	4	10
Net income attributable to Pfizer Inc. common shareholders		7,680	4,114	16,609	11,546
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		7,676	4,103	16,606	11,537
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		4	11	4	10
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 7,680	$ 4,114	$ 16,609	$ 11,546
EPS Denominator
Weighted-average number of common shares outstanding––Basic (shares)	[1]	5,545	5,875	5,581	5,899
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)		104	112	110	99
Weighted-average number of common shares outstanding––Diluted (shares)	[1]	5,649	5,986	5,690	5,998
Cash dividends declared per share (in dollars per share)		$ 0.36	$ 0.34	$ 1.08	$ 1.02
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[2]	3	5	2	3
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Com_2

Contingencies and Certain Commitments (Actions In Which We Are The Plaintiff) (Details)

1 Months Ended

3 Months Ended

9 Months Ended

Mar. 31, 2019Patents

Jun. 30, 2018Patents

Feb. 28, 2018Patents

Jan. 31, 2018Patents

Dec. 31, 2017Patents

Oct. 31, 2017Patents

Sep. 30, 2017Patents

Mar. 31, 2017Patents

Feb. 28, 2017Patents

Aug. 31, 2016Patents

Jun. 30, 2015Patents

Apr. 30, 2017PatentsDefendant

Sep. 29, 2019Patents

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly not infringed upon

4

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Number of patents not infringed upon

3

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly not infringed upon

4

Precedex Premix [Member] | Hospira Versus Gland [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents allegedly not infringed upon

6

Precedex Premix [Member] | Hospira Versus Hengrui [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents allegedly not infringed upon

6

Precedex Premix [Member] | Hospira Versus Baxter [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly not infringed upon

4

Number of patents due to expire in 2019

1

Number of patents due to expire in 2032

3

Patent Infringement [Member]

Gain Contingencies [Line Items]

Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings

2

Patent Infringement [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Patent Infringement [Member] | Pfizer Versus Ajanta [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Pfizer Versus Generic Companies [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents due to expire in December 2020

3

Number or patents due to expire in December 2025

1

Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Contingencies and Certain Com_3

Contingencies and Certain Commitments (Actions In Which We Are The Defendant) (Detail) £ in Millions	1 Months Ended
	Oct. 31, 2018manufacturer	Sep. 30, 2018lagoon	Nov. 30, 2017class_action	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Sep. 29, 2019Claim	Dec. 31, 2016GBP (£)
Loss Contingencies [Line Items]
Number of class actions filed | class_action			2
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed				4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				2
Docetaxel [Member] | Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer	8
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim						46,500
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim						1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon		2			2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £							£ 84.2

Contingencies and Certain Com_4

Contingencies and Certain Commitments (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Billions	Aug. 05, 2019	Feb. 12, 2019	Feb. 07, 2019	Sep. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Share repurchase agreement, amount			$ 6.8
Accelerated share repurchases, cash paid		$ 6.8
Shares repurchased (in shares)	33.5	130
Accelerated share repurchases, shares repurchased during period, percentage of agreement amount			80.00%
Accelerated share repurchases, final price paid per share (in dollars per share)	$ 41.42
Remaining authorized repurchase amount				$ 5.3

Segment, Geographic and Other_3

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		9 Months Ended	12 Months Ended
		Sep. 29, 2019USD ($)Operating_Segment	Dec. 31, 2018USD ($)Operating_Segment
Segment Reporting [Abstract]
Number of segments | Operating_Segment		3	2
Assets | $	[1]	$ 170,446	$ 159,422
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other_4

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Earnings	[1],[2]	10,727	4,177	19,190	12,831
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,303	12,458	36,964	37,040
Earnings	[2]	7,856	8,257	24,062	24,428
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(1,443)	(1,298)	(3,750)	(3,605)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(1,141)	(1,309)	(3,357)	(3,665)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(300)	(112)	(152)	(221)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	7,187	298	6,495	452
Corporate and other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues		377	839	2,098	2,631
Earnings	[2]	(1,431)	(1,658)	(4,108)	(4,558)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	10,108	9,422	28,887	27,737
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		10,108	9,422	28,887	27,737
Earnings	[2]	6,503	6,206	18,484	17,987
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		2,195	3,036	8,077	9,302
Earnings	[2]	$ 1,353	$ 2,051	$ 5,577	$ 6,442
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018 , and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4.
[3]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million , (ii) charges for certain legal matters of $63 million , (iii) charges for business and legal entity alignment of $89 million , (iv) net gains recognized during the period on investments in equity securities of $3 million , (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B , Note 3 and Note 4. For Earnings in the third quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million , (ii) net charges for certain legal matters of $37 million , (iii) charges for business and legal entity alignment of $1 million , (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million , (ii) charges for certain legal matters of $72 million , (iii) certain asset impairment charges of $149 million , (iv) charges for business and legal entity alignment of $353 million , (v) net gains recognized during the period on investments in equity securities of $139 million , (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion , (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million , which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales , primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million , (ii) net credits for certain legal matters of $70 million , (iii) certain asset impairment charges of $31 million , (iv) charges for business and legal entity alignment of $5 million , (v) net gains recognized during the period on investments in equity securities of $460 million , (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million , which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4 .
[4]	The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Disease. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) .

Segment, Geographic and Other_5

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
(Charges) credits for certain legal matters	[1]	$ (64)	$ (37)	$ (84)	$ 70
Charges for business and legal entity alignment	[2]	87	1	343	5
Gains related to equity securities	[3],[4]	6	85	153	460
(Gain) on completion of Consumer Healthcare JV transaction	[5]	(8,087)	0	(8,087)	0
Research and development expenses	[5],[6]	2,283	2,008	5,827	5,549
External incremental costs		146		121
Loss on extinguishment of debt	[7]	0	0	(138)	(3)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		110	35	280	127
(Charges) credits for certain legal matters	[1]	(63)	(37)	(72)	70
Charges for business and legal entity alignment		89	(1)	353	5
Gains related to equity securities		3	85	139	460
Other (charges) income		641	286	738	89
Asset impairment charges				149	31
Loss on extinguishment of debt	[7]			(138)	(3)
Special one-time bonus paid to all non-executive Pfizer colleagues					119
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		43	91	184	226
GSK Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
(Gain) on completion of Consumer Healthcare JV transaction		(8,100)
GSK Consumer Healthcare [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
(Gain) on completion of Consumer Healthcare JV transaction		(8,100)		(8,100)
External incremental costs		161		223
Allogene [Member]
Segment Reporting Information [Line Items]
Non-cash pre-tax gain on contribution of assets					50
Allogene [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Non-cash pre-tax gain on contribution of assets					50
NovaQuest Co-Investment Fund V, L.P. [Member]
Segment Reporting Information [Line Items]
Research and development expenses		15
Charge in cost of sales for inventory build for eventual commercial use/expected future sale		127
NovaQuest Co-Investment Fund V, L.P. [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Charge in cost of sales for inventory build for eventual commercial use/expected future sale		127		127
Bain Capital [Member] | Cerevel [Member]
Segment Reporting Information [Line Items]
Gains related to equity securities			343		343
Bain Capital [Member] | Cerevel [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Gains related to equity securities			$ 343		$ 343
Therachon Asset Acquisition [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Research and development expenses		$ 337		$ 337
[1]	For the first nine months of 2018 , the net credits primarily represented the reversal of a legal accrual where a loss was no longer deemed probable.
[2]	In the third quarter and first nine months of 2019, and in the third quarter of 2018, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first nine months of 2018, mainly represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[3]	The third quarter of 2018 included gains of $24 million and the first nine months of 2018 included gains of $229 million related to our investment in ICU Medical stock. For additional information on investments, see Note 7B .
[4]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[5]	Amounts may not add due to rounding.
[6]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[7]	In the first nine months of 2019 , represents net losses due to the early retirement of debt in the first quarter of 2019, inclusive of the related termination of cross-currency swaps.

Segment, Geographic and Other_6

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Percentage Change In Revenue		(5.00%)		(2.00%)
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 5,850	6,361	$ 18,360	18,861
Percentage Change In Revenue		(8.00%)		(3.00%)
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 2,135	2,231	$ 6,450	6,657
Percentage Change In Revenue	[2]	(4.00%)		(3.00%)
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,585	1,640	$ 4,758	4,795
Percentage Change In Revenue	[3]	(3.00%)		(1.00%)
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 3,110	$ 3,066	$ 9,493	$ 9,358
Percentage Change In Revenue	[4]	1.00%		1.00%
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the third quarter of 2019 and $1.8 billion in the third quarter of 2018 , and were $5.2 billion in the first nine months of 2019 and $5.3 billion in the first nine months of 2018 .
[3]	Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey.

Segment, Geographic and Other_7

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	2,135	2,231	6,450	6,657
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,700	$ 1,800	$ 5,200	$ 5,300
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the third quarter of 2019 and $1.8 billion in the third quarter of 2018 , and were $5.2 billion in the first nine months of 2019 and $5.3 billion in the first nine months of 2018 .

Segment, Geographic and Other_8

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Revenue from External Customer [Line Items]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		12,680	13,298	39,062	39,670
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,141	977	3,418	2,820
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	236	197	632	558
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,248	1,239	3,703	3,928
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	10,108	9,422	28,887	27,737
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	2,207	2,182	6,754	6,529
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		1,025	870	3,121	2,524
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		276	261	825	789
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		182	204	542	605
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues		66	54	212	206
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		61	67	186	197
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		597	727	1,867	2,208
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	2,350	1,840	6,547	5,487
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,283	1,025	3,677	2,985
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		224	248	704	785
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		225	180	594	510
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		130	127	385	417
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		139	71	316	226
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		90	69	267	206
Oncology [Member] | Biopharma [Member] | Retacrit [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	64	19	147	55
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		194	101	456	302
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	1,917	1,841	5,717	5,944
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		163	145	505	464
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	109	110	348	369
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		87	87	265	294
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	77	61	254	243
Hospital [Member] | Biopharma [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues		92	68	238	215
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		61	50	195	184
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		62	76	185	221
Hospital [Member] | Biopharma [Member] | Zosyn/Tazocin [Member]
Revenue from External Customer [Line Items]
Revenues		49	56	153	176
Hospital [Member] | Biopharma [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		50	60	146	186
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	176	159	556	539
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues		335	300	961	929
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	656	669	1,910	2,124
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,808	1,845	4,795	4,708
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,603	1,660	4,268	4,290
Vaccines [Member] | Biopharma [Member] | FSME/IMMUN-TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		64	57	197	162
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]
Revenue from External Customer [Line Items]
Revenues		52	46	159	95
Vaccines [Member] | Biopharma [Member] | Trumenba [Member]
Revenue from External Customer [Line Items]
Revenues		73	61	117	95
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		16	21	54	65
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	1,226	1,184	3,482	3,419
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		599	432	1,634	1,221
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		415	531	1,285	1,589
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues	[2],[10]	155	166	446	469
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		43	40	92	104
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]
Revenue from External Customer [Line Items]
Revenues		15	14	24	36
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		601	531	1,592	1,651
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		125	132	372	420
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		124	143	357	416
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		104	117	319	388
Rare Disease [Member] | Biopharma [Member] | Vyndaqel [Member]
Revenue from External Customer [Line Items]
Revenues		156	37	259	108
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		64	64	192	195
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		28	38	94	123
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[5],[11]	2,195	3,036	8,077	9,302
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues		527	1,213	2,888	3,649
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		476	507	1,506	1,539
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		219	248	735	777
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		179	188	526	494
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues		120	137	379	509
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		80	78	242	228
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		74	72	217	223
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		68	76	201	233
Upjohn [Member] | Upjohn [Member] | Xanax [Member]
Revenue from External Customer [Line Items]
Revenues		50	52	147	163
Upjohn [Member] | Upjohn [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		24	53	122	163
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues		379	411	1,114	1,325
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[12]	$ 377	$ 839	$ 2,098	$ 2,631
[1]	Amounts may not add due to rounding.
[2]	Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
[3]	Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
[4]	The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Disease. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) .
[5]	We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation.
[6]	We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation.
[7]	Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne (f) . All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[8]	2018 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.
[9]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[10]	We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation.
[11]	Pfizer’s Upjohn business encompasses primarily off-patent branded and generic medicines that includes a portfolio of 20 globally recognized solid oral dose brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone.
[12]	On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 1A and Note 2B .

Segment, Geographic and Other_9

Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)	9 Months Ended
	Sep. 29, 2019brand
Upjohn [Member] | Upjohn [Member]
Schedule of Equity Method Investments [Line Items]
Number of off-patent legacy brands	20